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1 Summary CZE 
Dlaždicobuněčné nádory hlavy a krku jsou skupinou heterogenních tumorů 
vznikajících v epiteliálních buňkách aerodigestivního traktu a jsou charakteristické 
složitou diagnostikou, léčbou a prognózou onemocnění. Konzumace alkoholu, 
kouření a infekce vysoce rizikovými lidskými papillomaviry jsou 
velmi dobře popsané rizikové faktory výskytu nádorů hlavy a krku. Sinonasální 
karcinomy jsou skupinou nádorů vznikajících v dutině nosní a vedlejších dutinách 
nosních. Karcinomy orofaryngu jsou nádory vznikající v oblasti krku za ústní 
dutinou. 
mikroRNA (miRNA) jsou krátké (~23 nukleotidů) nekódující molekuly RNA 
účastnící se regulace genové exprese. Primární rolí mikroRNA molekul je negativní 
regulace translace jako součást komplexu RISC (komplex umlčující geny indukovaný 
RNA) pomocí represe translace a mRNA degradace. miRNA se účastní regulace 
procesů u mnoha onemocnění, jako jsou neurodegenerativní choroby, metabolické 
poruchy a malignity. Kromě toho jsou miRNA rozeznávány jako klíčové molekuly 
účastnící se kancerogeneze a progrese u různých typů nádorových onemocnění. 
Ve své výzkumné práci v rámci doktorského studia jsem se zaměřila na výzkum 
relativní exprese několika dříve vytipovaných mikroRNA s využitím real-time PCR. 
A dále jsme zkoumali korelaci jejich expresních profilů se zaznamenanými 
klinickopatologickými daty pacientů se sinonasálním dlaždicobuněčným 
karcinomem a orofaryngeálním dlaždicobuněčným karcinomem. Zkoumané 
mikroRNA byly vybrány na základě literární rešerše zaměřené na ostatní typy 
dlaždicobuněčných karcinomů hlavy a krku (v případě studie u sinonasálních 
karcinomů) a na základě výsledků dvou vysoce-výkonných metod (miRNA 
microarray a sekvenování nové generace malých RNA) ve fázi I studie zaměřené 
na karcinom orofaryngu. Na základě výsledků exprese miRNA a následné statistické 
analýzy, jsem došla k závěru, že miR-9 (mimo dalších miRNA) by mohla být dobrým 
potenciálním biomarkerem sinonasálního dlaždicobuněčného karcinomu 
a miR-150-5p, mimo dalších miRNA, by mohly být dobrým potenciálním 
biomarkerem orofaryngeálního dlaždicobuněčného karcinomu.  
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2 Summary ENG 
Head and neck squamous cell carcinomas are a group of heterogenic tumors 
arising from epithelial tissue of aerodigestive tract characterized by difficult 
diagnosis, treatment and prognosis. Alcohol consumption, smoking and high-risk 
human papillomavirus infection are very well described risk factors of head and neck 
cancer development. Sinonasal carcinomas are group of malignancies developing 
in nasal and paranasal sinuses. Oropharyngeal carcinomas are malignancies 
developing in the throat area downstream to oral cavity. 
microRNAs (miRNAs) are short (~23 nucleotides) non-coding RNA molecules 
participating in regulation of gene expression. Primary function of miRNAs 
is negative translation regulation as part of RISC (RNA-induced silencing complex) 
by translational repression and mRNA degradation. miRNAs are involved in various 
disease pathologies such as neurodegenerative diseases, metabolic disorders 
and cancer. Moreover, microRNAs have been recognized as key molecules in cancer 
development and progression in various types of tumors. 
My doctoral study research activities were focused on investigation of relative 
expression of several preselected miRNAs (using real-time PCR) and the relationship 
between their expression and clinicopathological characteristics of the squamous 
cell carcinoma and oropharyngeal carcinoma patients. miRNAs of interest for this 
study were selected based on literary review focused on other types of squamous cell 
head and neck cancer (sinonasal cancer study) and two high-throughput miRNA 
expression methods (miRNA microarray and small RNA Next-generation 
sequencing) in the phase I of the oropharyngeal cancer study. Based on miRNA 
expression results and statistical analysis, I have concluded that (among others) 
miR-9 might be the best potential biomarkers for sinonasal squamous cell carcinoma 
and miR-150-5p (among others) may be the best potential biomarker 




3 Used abbreviations 
AC Adenocarcinoma 
ac-pre-mir-451 Ago-cleaved pre-mir-451 
AdCC Adenoid cystic carcinoma 
Ago2 Argonaute2 
AUC Area under the Receiver operating characteristics curve 
BCL B-cell lymphoma 
C00-C14 Malignant neoplasm of lip, base of tongue, 
other and unspecified parts of tongue, gum, floor of mouth, 
palate, other and unspecified parts of mouth, parotid gland, 
other and unspecified major salivary glands, tonsil, 
oropharynx, nasopharynx, pyriform sinus, hypopharynx, 
other and ill-defined sites in the lip, oral cavity and pharynx 
C30 – C32 Malignant neoplasm of nasal cavity and middle ear, 
accessory sinuses and larynx 
C30.0 Malignant neoplasm of nasal cavity 
C31 Malignant neoplasm of accessory sinuses 
CDDP Cis-diaminodichlorplatine 
CDK6 Cyclin-D kinase-6 
CI Confidence interval 
CLL Chronic lymphocytic leukemia 
CpG Cytosine-guanine dinucleotide 
CSCs Cancer stem cells 
DE Differential expression 
DGCR8  DiGeorge Syndrome Critical Region 8 protein 
DMSO Dimethylsulfoxid 
DNMT DNA methyltransferase  
dsDNA Double-stranded DNA molecule 
EBV  Epstein Barr virus 
EMT Epithelial-mesenchymal transition  
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epi-miRNAs miRNAs targeting epigenetic machinery 
ER Error rate 
Exp5  Exportin-5  
HNC Head and Neck Cancer 
HNSCC  Head and neck squamous cell carcinoma 
HPV- HPV negative 
HPV Human papillomavirus 
HPV+ HPV positive 
HR-HPV High-risk Human Papillomavirus 
IMRT Intensity-modulated radiation therapy 
ITAC Intestinal-type adenocarcinoma 
LEC Lymphoepithelial carcinoma 
miRBase microRNA Registry  
miRNA microRNAs 
miRNome microRNA expression signature profile 
moRs  microRNA-offset RNAs 
mRNA Messenger RNA 
MS-HRM Methylation-sensitive high-resolution melting 
NGS Next-generation sequencing 
NTC No template control 
NUT Nuclear protein in testis 
NUT Nuclear protein in testis gene  
oncomiRs  Oncogene miRNAs 
OPSCC Oropharyngeal squamous cell carcinoma 
PARN  Poly(A)-specific ribonuclease  
precursor miRNA pre-miRNA 
pri-miRNA Primary miRNA transcript 
pRNA Piwi-interacting RNA 
Rb Retinoblastoma 
RIN RNA integrity number 
RISC  RNA-induced silencing complex 
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ROC Receiver operating characteristics 
rRNA Ribosomal RNA 
SAH S-adenosyl-homocysteine 
SAM S-adenosyl-methionine;  
SCC Squamous cell carcinoma 
SCNEC Small cell neuroendocrine carcinoma 
SE Sensitivity 
shRNA  Short hairpin RNAs 
SMARCB1/INI1 SWI/SNF-related matrix-associated actin-dependent 
regulator of chromatin subfamily B member 1/integrase 
interactor 1  
SNAC Non-intestinal type adenocarcinoma 
SNC Sinonasal Carcinoma 
snoRNA Small nucleolar RNA 
snRNA Small nuclear RNA 
SNUC Sinonasal undifferentiated carcinoma 
SP Specificity 
sRNA Small RNA 
SSCC Sinonasal squamous cell carcinoma 
TC Typical carcinoid 
TCGA  Cancer Genome Atlas 
TE Transposable element  
TRBP  Transactivating response RNA-binding protein  
tRNA  Transfer RNA 
VMAT  Volumetric modulated arc therapy 





4 Background     
4.1 Head and Neck Cancer 
Head and neck cancer (HNC) is a group of heterogenic tumors arising 
from epithelial tissue of aerodigestive tract including cancers of the lip, tongue oral 
cavity and gum, nasal cavity, nasal sinuses, salivary gland, nasopharynx, oropharynx, 
hypopharynx and larynx (Figure 1). Head and neck cancers are predominantly 
squamous cell carcinomas (HNSCC), which make up to 90 % of head and neck 
cancers worldwide. Squamous cell carcinoma (SCC) is also the most commonly 
researched subtype of HNC [1].  
 
Figure 1. Anatomical subsites of Head and Neck Cancer [2]. 
Alcohol consumption and smoking are risk factors for developing head and neck 
cancer especially in oral cavity and oropharynx. Human papillomaviral (HPV) 
infection dramatically increases the risk of oropharyngeal carcinoma and oral cancer 
[3].  The first choice of treatment of HNC in early stages is usually a surgery usually 
combined with radiotherapy. Whereas, in later stages of the disease combination 
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of surgery with post-operational radiotherapy and radical chemotherapy using 
cis-platin derivate is recommended [4]. 
Worldwide, there are more than 550,000 of new cases of head and neck cancer 
diagnosed annually and 380,000 HNC patients die every year [2]. HNCs more 
commonly occur in men than in women in 2:1 to 4:1 ratio [5]. The highest prevalence 
of HNC is in developing countries especially in South-East Asia, which has been 
linked to popularity of chewing betel nuts in the region [6]. Five-year survival 
of HNC patients is 40 % and it is dependent upon the original anatomical site 
affected, stage and HPV status of the tumor [7; 8]. The incidence of these tumors 
is in the Czech Republic 21.27/100,000 and mortality rate is 10.38/100,000 
(the latest data available is from 2016) (we included following diagnosis 
to the analysis: C00 – C14, C30 – C32) [9].  
4.1.1 Sinonasal cancer 
Sinonasal carcinomas (SNC) are group of malignancies developing in nasal and 
paranasal sinuses which make up 3 % to 5 % of all head and neck cancers and 1 % 
of all kinds of tumors [10; 11]. Half of the cases are located in a nasal cavity, 
while other tumors originate in maxillary and ethmoid sinuses. Finally, tumors 
in frontal and sphenoid sinuses are rare (Figure 2). The most common subtype 
of sinonasal cancer is sinonasal squamous cell carcinoma (SSCC), although 
it represents smaller proportion of cases than in other types of head and neck 
cancers (65 – 75%). SSCC are further classified as non-keratinizing or keratinizing, 
when non-keratinizing tumors are more likely to be linked to high-risk HPV 
(HR-HPV) infection. Other squamous cell tumors of this site can be classified 
as basaloid SCC, papillary SCC or spindle cell carcinoma. Lymphoepithelial 




Figure 2. Sinonasal carcinoma regions [13], adjusted.  
Areas, where sinonasal cancer can arise are highlighted by blue boxes. 
Other types of carcinomas are intestinal-type adenocarcinomas (ITACs) 
and non-intestinal sinonasal adenocarcinomas (SNACs), which has been strongly 
associated with wood-dust exposure. Sinonasal undifferentiated carcinoma (SNUC) 
is not a very common sinonasal tumor, which is diagnosed by exclusion 
of neuroendocrine carcinomas including small cell carcinoma and large cell 
neuroendocrine tumors. In the newest version of 2017 WHO classification system 
of tumors new categories of tumors were described. NUT midline carcinoma (NMC) 
is defined by rearrangement of the NUT (nuclear protein in testis) gene and in many 
cases, it arises from sinonasal tract mediastinum [14; 15]. SMARCB1 (INI-1) deficient 
sinonasal carcinoma is characterized by loss of expression of SMARCB1/(INI-1) 
protein [16] (Table 1). 
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Table 1. Summarization of SNC subtypes and their characteristics. 
Tumor type Subtype Characterization Association 
Squamous cell 
carcinoma 
Keratinizing   
Non-keratinizing  HR-HPV 
Basaloid  HR-HPV 
Papillary  HR-HPV 





























 RB-1 gene mutation  
NUT carcinoma  






Loss of expression of 
SMARCB1/INI-1 
 
EBV, Epstein Barr virus; HR-HPV, High-risk Human Papilloma Virus; NUT, 
nuclear protein in testis. 
Incidence of SNC (diagnosis codes C30.0 and C31) is less than 5 % in a million. 
Specifically, in the Czech Republic in 2016 the incidence was 0.5/100,000 
and mortality was 0,23/100,000. The tumors are more common in men 
than women, which is caused by increased risk of sinonasal cancer development 
due to risk of professional exposure in predominantly male occupations. The tumors 
usually appear in advanced age (mean; approximately 62 years of age) [17]. 
Even though aggressive combined treatment is usually used, survival median is less 
than 18 months and 5-year survival rate is only 20 % — 30 % [18]. Early symptoms 
of the disease are rhinorrhea, epistaxis, epiphora, and nasal obstruction. Advanced 
lesion symptoms include blurred vision, diplopia or proptosis [19]. 
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Thanks to non-specific symptoms, patients often develop highly advanced tumors 
with extensive invasion to neighboring tissues such as eyes, optic nerves and chiasm.  
Due to complexity of the region and proximity of several important structures 
treatment of the tumors is challenging and it is often necessary to utilize 
multimodality therapeutic approach. The treatment is usually based on radical 
surgical resection with postoperative radiotherapy. Treatment effects have improved 
due to new endoscopic surgical approaches and involvement of new radiation 
techniques such as IMRT, volumetric modulated arc therapy (VMAT) and proton 
or heavy ion therapy that allow targeted high dose of radiation. Neo-adjuvant 
(induction) chemotherapy with cis-platin derivate can be used to reduce the tumor 
size prior to surgery [20]. 
One of the risk factors involved in SNC carcinogenesis is cigarette smoking. 
Specifically, cigarette smoke inhalation has the largest impact on squamous cell 
sinonasal carcinoma [21]. The influence of HPV infection on SNC carcinogenesis has 
been studied recently. Approximately 20 – 30 % of SNC tumors harbor 
transcriptionally active HPV infection, which is a lower proportion in comparison 
to other head and neck tumors [22]. High risk HPV type 16 is the most aggressive 
type which has been found in about 90 % of HPV+ cases of SSCC. Patients 
with HPV+ tumors have much better prognosis than patients with HPV- tumors [23-
25].  
Professional exposure to specific cancerogenous substances (such as wood-dust, 
leather-dust and formaldehyde) is another established risk factor for SNC 
development [26]. Dangerous professions include wood workers (cabinetmakers, 
carvers or carpenters), who often inhale wood-dust. Mechanism of SNC 
development due to wood-dust (especially from hard wood types) have been 
clarified studying ITACs. Hard wood-dust inhalation causes chronic inflammation 
in sinonasal area, which leads to TP53 mutagenesis and subsequently 
to carcinogenesis in the area [27]. Moreover, in danger of SNC development are 
leather industry workers (shoe manufacturers and tanner workers) 
due to leather-dust inhalation, individuals exposed to nickel compounds 
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in electrolytic nickel refining and alkaline battery manufacturers or employees 
exposed to formaldehyde [21; 28]. 
4.1.2 Oropharyngeal cancer 
Malignancies developing in the throat area downstream to oral cavity are called 
oropharyngeal cancers. Oropharynx is located between the soft palate and hyoid 
bone and it consists of base of the tongue, tonsillar region, soft palate and uvula 
and posterior and lateral pharyngeal walls (Figure 3). Tonsils are the most common 
subsites of the disease followed by base of the tongue. Patients with oropharyngeal 
cancer might manifest symptoms such as persistent sore throat, odynophagia, 
otalgia, dysphagia or globus sensation [29; 30]. Almost all cases of oropharyngeal 
cancer are squamous cell carcinomas (OPSCC), other subtypes such 
as adenocarcinomas are rare.  
 
Figure 3. Anatomy subsites of oropharyngeal cancer [31], adjusted.  
Oropharyngeal cancer sites of origin are highlighted by blue boxes. 
Most of the oropharyngeal squamous cell carcinoma tumors develop 
from premalignant lesions such as leukoplakia, erythroplakia and oral submucous 
fibrosis that can be often asymptomatic [32]. Prevalence of OPSCC is on the rise 
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globally (especially in the US and Western countries), while incidences of other 
types of head and neck cancer are decreasing. Traditional risk factors include 
excessive tobacco smoke and alcohol exposure (with multiplicative effect) and low 
socioeconomic status [32; 33]. In the “high tobacco consumption era” the incidence 
of oropharyngeal cancer was similar to other malignancies of upper aerodigestive 
tract and the occurrence of comorbidities was high within the patients [34]. Recently 
oncogenic human papillomavirus, especially p-16, has emerged as another factor 
of oropharyngeal carcinogenesis. Particularly tumors developing in the base 
of the tongue and tonsils are mostly HPV+, which is caused by microanatomy 
of the reticulated epithelium lining that contains immune system component. 
Consequently, it can harbor HPV antigens without causing immune inflammatory 
response [34].  
The incidence of oropharyngeal cancer (diagnosis codes C09, C10) in the Czech 
Republic (estimated data for 2019) is 5.2/100,000 with rising tendency and mortality 
1.8/100,000, which is above European average [35]. Patients with HPV negative 
tumors are usually older (mean; 66 years of age) and have a history of tobacco and 
alcohol abuse. On the other hand, patients with virally induced HPV (p16) tumors 
tend to be younger (mean; 59 years of age), have small primary tumors 
with extensive nodal involvement and may have history of dangerous sexual 
behavior [34]. However, they have better prognosis than patients with HPV negative 
tumors. Frequently, neck nodal metastases without clinically obvious primary 
lesions are present. Nodal metastases are frequently large with pushing borders and 
expansion of the lymph nodes rather than extensive infiltration of the surrounding 
tissue [14].  
Decline in number of head and neck cancers has been attributed to decline 
in alcohol and tobacco use in society. Conversely, it has been concluded that 
increasing number of OPSCC cases might correlate with rising incidence of virally 
induced HPV cancers and changes in sexual trends (especially oral sex popularity) 
[36]. Since HPV positive tumors show good response to treatment regardless what 
kind of therapy is used, it has been suggested that older versions of TNM 
classification are no longer sufficient for oropharyngeal tumor classification. 
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Therefore, HPV positive and HPV negative tumors are currently recognized as two 
clinically different entities [37-41]. Therapy of OPSCC in majority of the cases used 
to be limited to surgery with subsequent radiation therapy. Recently, new treatment 
approaches, such as immune therapy, have emerged. Advanced radiotherapy 
techniques and intensity-modulated radiation therapy (IMRT) allow more accurate 
dose delivery focused specifically on the tumor. HPV+ tumor treatment approaches 
have been de-intensified in response to better understanding of their biology. 
Surgical therapy can nowadays utilize state-of-the-art techniques such as robotic 
or laser surgery [34]. 
4.2 Epigenetic modifications 
Epigenetic changes are defined as heritable changes in gene expression, 
which are not accompanied by DNA sequence modifications. They comprise of DNA 
methylation, covalent histone modification and posttranscriptional modifications 
by microRNAs (miRNAs).  
Histone modifications are alterations in chromatin structure and they are caused 
by posttranslational modifications of histone proteins such as acetylation, 
methylation and phosphorylation. DNA in cell nucleus is packed in chromatin 
resulting in forming a dynamic structure consisting of nucleosomes. Nucleosomes 
are composed of 147-base pair segments of DNA wrapped around octamer of four 
core histone proteins (H3, H4, H2A and H2B) [42]. Acetylation of lysine residues 
in histone molecules is catalyzed by histone-acetyltransferases. This process leads 
to structural changes in nucleosomes, which enables transcription factors to access 
promotors of gene locuses, subsequently, leading to transcription initiation. 
Acetylation is a reversible process which is catalyzed by enzymes called 
histone-deacetylases. Proper function of posttranslational histone modifications 




microRNAs are short (approximately 23 nucleotides long) non-coding RNA 
molecules participating in regulation of gene expression. The first evidence 
of their existence was published by Lee et al. in 1993 [44] as a result of experiments 
with Caenorhabditis elegans. All information about annotated mature miRNAs 
and their hairpin sequences are summarized in searchable online reference database 
miRbase (“microRNA registry”). The newest version (Release 22.1, October 2018) 
of miRbase contains 38,589 entries in total, from which 1,917 are human miRNA 
precursors and 2,654 human mature miRNA entries [45; 46]. Primary function 
of miRNAs is negative translation regulation as a part of RISC (RNA-induced 
silencing complex) by translational repression and mRNA degradation. mRNA decay 
is induced by endonucleolytic cleavage by RISC in case of perfect or nearly perfect 
base pairing of miRNAs to the targeted mRNA. However, mammalian miRNAs more 
often recognize the target mRNA by partial complementarity within the so called 
“seed region”, which are nucleotides 2 – 7 or 2 – 8 of the miRNA. In this case 
of imperfect complementarity, mRNA is silenced by translational repression 
of additional effector proteins [47].  
About half of the known miRNAs have been identified as intragenic, meaning 
they are embedded in the introns of non-coding genes and some exons of protein 
coding genes. The rest of the miRNAs are intergenic. They are transcribed 
independently of a host gene and transcription regulation is done by their own 
promoter. Some cluster miRNAs are transcribed as one long transcript prior 
to cleavage considered as a miRNA family. microRNAs can target up to several 
hundred mRNAs, which makes them powerful regulators in various pathways. 
They have been established as key molecular components of the cell in both normal 
and pathologic states [48]. Target mRNAs of known miRNAs were either 
experimentally verified (small fraction) or predicted by various algorithms. 
Algorithms based on conservation criteria are used by following tools: PicTar [49], 
Target Scan [50]. However, DIANA-microT [51], PITA [52] and RNA22 [53] use 
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other parameters such as free energy of secondary structures of 3’ UTRs promoting 
or preventing miRNA binding [54].  
4.2.1.1 microRNA biogenesis 
The canonical pathway of miRNA biogenesis (Figure 4) starts with transcription 
of the appropriate sequence by RNA polymerase II resulting in creation of primary 
miRNA transcript (pri-miRNA) located in nucleus. Pri-miRNA is then cleaved 
by microprocessor complex of RNA binding protein DGCR8 (DiGeorge Syndrome 
Critical Region 8) and ribonuclease III enzyme Drosha forming a characteristic 70 
nt long loop structure of precursor miRNA (pre-miRNA). This structure 
is transported by export factor Exportin-5 (Exp5) into cytoplasm, where second 
cleavage (loop removal) is performed by another ribonuclease II enzyme Dicer 
resulting in a mature miRNA duplex formation. Directionality of the processed 
miRNA strand determinates its mature name; 5p miRNAs originate from 5’ end and 
3p miRNAs are created from 3’ strand. One of the duplex strands is joined to the 
RISC complex compiling of Argonaute2 protein (Ago2), Dicer and TRBP 
(transactivating response RNA-binding protein). In this complex miRNA is the key 
to mRNA target recognition during RNA interference.  The other strand of mature 
miRNA is called the passenger strand, in the past labeled with *, and it is 




Figure 4. The canonical pathway of miRNA biogenesis.  
Pol II, RNA polymerase II; pri-miRNA, primary miRNA transcript; DGCR8, 
DiGeorge Syndrome Critical Region 8 protein; pre-miRNA, precursor miRNA 
loop structure; Exp5, Exportin-5; RISC, RNA-induced silencing complex; 
TRBP, transactivating response RNA-binding protein; Ago2, Argonaute2 
protein. 
Furthermore, about 1 % of conserved miRNAs are produced by different 
non-canonical pathways (Figure 5), which have been recently described. 
Their structural and functional resemblance to canonical miRNAs was discovered 
thanks to development of deep sequencing techniques [57; 58]. Non-canonical 
miRNAs can have various origins such as mirtrons, snoRNAs (small nucleolar RNAs), 
endogenous shRNAs (short hairpin RNAs) and tRNAs and can be produced 
by Microprocessor-independent or Dicer-independent way. The first describe 
non-canonical pathway is mirtrons production. Mirtrons are produced from introns 
of mRNA genes [55]. In this pathway Drosha and DGCR8 mediated step is skipped 
and miRNA precursor is processed by mRNA splicing. After splicing of host mRNA, 
the assembly refolds into a short stem-loop pre-miRNA like structure. 
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Some mirtrons are characterized by having extra sequences at the 5’ or 3’ end, 
which are ultimately trimmed by exonucleases.  
 
Figure 5. Non-canonical biogenesis of miRNAs.  
A) Drosha and DGCR8-independent pathway, where mirtrons are first 
transcribed in the introns of genes and then spliced. Finally, pre-miRNAs are 
processed by Dicer and joined to the Ago2 protein ultimately forming RISC. 
B) Dicer-independent pathway of miRNA biogenesis. Pri-miRNAs are firstly 
cleaved by Drosha and then attached to Ago2, where they are cleaved 
and ultimately trimmed by PARN. 
Cap, 5’ Cap RNA modification; A(n), 3’ Polyadenylation RNA modification; 
Ago2, Argonaute 2 protein; RISC, RNA induced silencing complex; PARN, 
Poly(A)-specific ribonuclease.  
Small RNAs (sRNA) derived from shRNAs are generated through direct 
transcription and not cleaved by Drosha. However, they still depend on Dicer 
processing. In the other case of non-canonical (erythropoietic miR-451) biogenesis 
is independent on Dicer and it relies on catalytic activity of Ago2. Drosha-mediated 
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processing of pri-miR-451 creates short hairpin with stem of ~18 bp that is too short 
to be processed by Dicer. Consequently, pre-miR-451 is immediately attached 
to Ago2 and cut in the middle of its 3’ strand leading to 30-nucleotide long 
Ago-cleaved pre-mir-451 (ac-pre-mir-451). Mature miR-451 (~23 nt in length) 
is produced by Poly(A)-specific ribonuclease PARN by trimming the 3’ end 
of ac-pre-mir-451 (Figure 5) [57]. Non-canonical miRNAs have been linked 
to various pathological processes such as psoriasis, ischemic disease, diabetes 
mellitus or epithelial malignancies [58]. 
4.2.1.2 microRNA nomenclature 
Continual improvement of deep sequencing techniques has brought increase 
in number of published miRNA reads obtained from next generation sequencing 
experiments. Some of the captured miRNAs and miRNA genes are indeed new, 
some of them have been previously described in other than human species. New 
sequencing approaches also put focus on isomiRs. They are variants of the same 
miRNA sequences derived from the same gene, but they vary in sequence 
due to posttranscriptional processing and may have different functions in cells. NGS 
has also exposed sequences called moRs (microRNA-offset RNAs), which are 
considered as byproducts of miRNA biosynthesis without any biological 
significance. Sequencing experiments have also revealed single strand RNA 
fragments originating in the loopRNA portion of pre-miRNA hairpin called 
loop-origin miRNAs (loRs). However, biological relevance of these variants is not 
fully understood yet [59; 60].  
Nomenclature guidelines for novel miRNAs to be included in miRBase require 
experimentally confirmation by cloning or verification with evidence of expression 
and processing. New miRNAs always have sequential identifiers assigned. 
Information about the species are coded in three letter prefixes (“hsa” is code 
for human miRNA, “mmu” is mouse, etc.). The mature miRNA sequences are coded 
as “miR” and precursor miRNAs are labelled with “mir”. The number codes for the 
same miRNAs in different species tend to be in preserved, as a result hsa-miR-101 
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in human and mmu-miR-101 in mouse are orthologues. Sequences with 1 or two 
nucleotide difference are called paralogues and are given letter suffixes (for example 
a, b and c). Mature miRNAs arising from the same hairpin loci are differentiated 
by number suffixes (-1 or -2). Moreover, two different mature miRNAs are named 
after the opposite  arms of the same hairpin precursor (-5p suffix marking miRNAs 
originating from 5’ end and -3p suffix a code for miRNAs originating at the 3’ arm 
of the hairpin) [61; 62]. 
4.2.1.3 microRNAs and cancer 
miRNAs are involved in various diseases such as neurodegenerative diseases, 
metabolic disorders and cancer. Connection between microRNA and cancer was first 
described by Calin et al. in 2002 [63]. They discovered, that miR-15 and miR-16 genes 
are localized on chromosome 13q14, which is an area frequently deleted (65 %) 
in patients with chronic lymphocytic leukemia (CLL). Deletion of the two miRNAs 
causes form of the disease non-responsive to treatment. Lu et. al [64] were first 
to describe that miRNA expression profile varies in different types of cancerous 
tissue. Moreover, they observed deregulation of some miRNAs when comparing 
tumor samples and control samples (today whole miRNA expression signature 
is known as miRNome).  Finally, they discovered that expression of miRNAs varies 
even within the patients’ group, so researchers might be able to predict progression 
of the disease and site of origin of the tumor. microRNAs regulate several 
cancer-linked processes such as cell proliferation, apoptosis, migration and invasion, 
angiogenesis, immune evasion, cell differentiation, formation of cancer stem cells 
(CSCs) and epithelial-mesenchymal transition (EMT) phenotype gain. miRNA 
profiles might able to distinguish not only between normal and cancerous tissue, 
but also between different subgroups of tumors, predict outcome and patient’s 
survival or response to therapy or specific drug resistance.  
microRNA expression mimics the expression of other cancer associated genes. 
Therefore, it can be altered by chromosomal amplification/deletion, promoter 
methylation and transcription factor activation. miRNAs in cancer can work 
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as oncomiRs (their upregulation is associated with cancer development) 
or tumor-suppressors (their negative regulation promotes carcinogenesis) [48]. 
Information about miRNAs involved in various types of cancer development are 
included in the Cancer Genome Atlas (TCGA) [65]. 
Recently, different expression of circulating miRNAs in biological fluids (such as 
plasma or serum, saliva, urine and amniotic fluid) of the patients was discovered, 
which suggests that miRNAs could be utilized as potential clinical biomarkers 
for diagnostics, treatment response prediction, remission and relapse prediction, 
monitoring and prognostic purposes. Using circulating miRNAs for diagnosis might 
precede conventional methods. Unprotected miRNAs are sensitive to degradation 
by RNases naturally occurring in blood. Therefore, circulating miRNAs can be bound 
to RNA-binding proteins, high density lipoproteins or encapsulated within 
extracellular vesicles (EVs) [66]. Ultimately microRNAs might be useful in cancer 
therapy by interfering with molecular  mechanisms of tumorigenesis [67]. Various 
pre-clinical trials have shown that miRNAs have great potential as cancer 
therapeutics, however, no miRNAs have been approved for clinical use yet. 
After several pre-clinical studies were concluded as a success, miR-34a mimic 
replacement therapy development for clinical use started. In April 2013 miRNA 
mimic bounded in liposomes (MRX34) was the first miRNA-based drug to enter 
phase I clinical trial. In 2016 the trial was terminated due to immune-related severe 
side effects of the treatment in five patients [68].  
4.2.1.4 microRNA and head and neck cancer 
Current research on epigenetics and miRNA involvement in head and neck 
cancer biogenesis is mainly focused on the most prevalent tumor subtypes 
and subsites: squamous cell carcinoma of oral cavity, larynx and oropharynx. 
Most of the differentially expressed miRNAs in HNSCC could be divided into 
following categories: miRNAs related to tumor invasiveness and metastases 
development (for example miR-200 family), oncogenic miRNAs (oncomiRs) (miR-21 
is the most studied and wildly deregulated miRNA in this category) and miRNAs 
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associated with HPV status or smoking (for example miR-9 and miR-145) [69]. Many 
teams investigate differentially expressed miRNAs in HNSCC compared to normal 
epithelial tissue. Deregulation of several miRNAs was consistently reported 
in several studies including: miR-21, miR-31, miR-106b-25 cluster, miR-155, miR-363 
and let-7, which were upregulated, and miR-125 and miR-375, which were 
downregulated [70].  
Ogawa et al. [71] studied correlation between downregulation of miR-34a 
and resistance to cis-diaminodichlorplatine (CDDP) treatment in sinonasal cancer. 
Authors concluded that miR-34a and other miRNA species might be involved 
in regulation of tumor chemosensitivity to CDDP treatment. Zhao and Wang [72] 
confirmed downregulation miR-34a in sinonasal squamous cell carcinoma 
and its association with poor prognosis of the patients. They suggested that miR-34a 
limits migration and invasiveness of SSCC cells by targeting BCL-2. Tomasetti et al. 
reported potential role of miR-126 as a diagnostic biomarker to differentiate 
malignant Sinonasal Intestinal-type Adenocarcinoma [73].  
Research on miRNA expression levels in OPSCC is nowadays mainly focused 
on miRNome differences in HPV positive and HPV negative tumors. It has been also 
discovered that HPV genomes encode their own miRNAs. The role of these miRNAs 
has not been experimentally verified, however, target prediction algorithms suggest 
regulation of HPV genome itself (within HPV genes E5, E1, L1 and LCR region) as well 
as host genome targets [74]. The most studied miRNAs in OPSCC include miR-31, 
which might play oncogenic role in tumor development. Then, if miR-24 
is upregulated, enhances cancer cell proliferation and reduction in apoptosis occurs. 
On the other hand, miR-146a functions as tumor-suppressor and it is associated 
with favorable prognosis of the disease [75]. 
4.2.2 DNA methylation 
DNA methylation is an epigenetic modification, in which methyl group is added 
to C5 position of cytosine in cytosine-guanine (CpG) dinucleotide. Methylation 
is catalyzed by enzyme DNA methyltransferase, which transfers methyl group 
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from S-adenosyl-methionine. DNA methylation results in formation 
of 5’methyl-cytosine (Figure 6).  
 
Figure 6. DNA methylation. 
Methyl group is added to C5 cytosine. DNMT, DNA methyltransferase; 
SAM, S-adenosyl-methionine; SAH, S-adenosyl-homocysteine. 
CpG dinucleotides are not equally distributed throughout the genome, but they 
are focused on areas with higher density of CpG dinucleotides called CpG islands. 
These areas are usually localized on promotor/first exon regions of the genes [76; 
77]. The methylation of cytosine’s is catalyzed by class of enzymes called DNA 
methyltransferases (DNMTs). Their primary purpose is to catalyze transfer 
of the methyl group from S-adenosyl-methionine to cytosine. Three DNMT families 
have been identified in mammals. DNMT1, DNMT2, DNMT3a, DNMT3b 
and DNMT3L. DNMT3a a DNMT3b work as de novo methylation enzymes, whereas, 
DNMT1 serve as maintenance enzymes of parental DNA pattern restoration. The rest 
of the DNA methyltransferases does not work as cytosine methyltransferases [78]. 
DNA methylation is important for 1) proper embryonic development, 2) 
chromosome X deactivation, 3) imprinting and 4) silencing transposable elements 
(TEs) [79].  
Cancer cells are characterized by different methylation patterns from normal 
cells. However, both hypomethylation and hypermethylation changes can be 
observed in cancer. Global decrease of methylated CpGs results in genomic 
instability and alternatively activation of silenced oncogenes. Hypermethylation 
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of CpG islands in promotor regions of specific genes is a common characteristic 
of many cancer cells acting as tumor-suppressors in healthy tissue. 
4.2.2.1 DNA methylation and microRNAs 
About 50 % of miRNA genes are surrounded by CpGs, so they can be regulated 
by hypermethylation or hypomethylation. Expression of miRNAs located in introns 
of the host genes is usually regulated by one shared promotor (Figure 7) [80]. 
miRNAs acting as tumor-suppressor genes might be silenced by hypermethylation 
of CpG islands in their own promoter regions  [78]. It has been discovered that DNA 
hypermethylation silencing of miR-124a leads to Cyclin-D kinase-6 (CDK6) 
overexpression and higher phosphorylation of retinoblastoma (Rb). When Rb 
is phosphorylated by CDK6, it loses its anti-proliferative activity. This miRNA 
hypermethylation has been also observed in glioblastoma multiforme, gastric 
cancer, hematopoietic malignancies, cervical cancer and hepatocellular carcinoma. 
One of the well-known tumor-suppressor miRNAs is miR-145 and its deregulation 
by promoter DNA methylation was reported in many human cancers to lead 
to pluripotency reacquisition. Other miRNAs regulated by DNA methylation 




Figure 7. Regulation of tumor-suppressor miRNAs by DNA methylation.  
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In normal cells regulatory (promoter) regions are unmethylated, coded 
miRNAs are expressed and may target mRNAs. However, in cancer cells 
miRNA expression is suppressed by their promoter methylation and cannot 
inhibit mRNA translation. Therefore, oncogenes normally silenced 
by miRNAs can be expressed.  
A) Some of miRNAs are regulated by their own promotor, so methylation 
of CpGs in the promotor region leads to loss of expression.  
B) miRNAs localized in the introns of host genes can be regulated by host 
gene methylation.  
C) Even miRNAs located in the host genes can have their own promoter, 
which can be methylated. 
miRNAs targeting directly or indirectly effectors of epigenetic machinery such 
as DNMTs are called epi-miRNAs. miR-29 was the first experimentally verified 
epi-miRNA. Epigenetic targets of miR-29a, b and c are DNMT3A, DNMT3B 
and DNMT1. Other miRNAs such as miR-143 also regulate methylation (targeting 
DNMT3A), miR-148a,b (targeting DNMT1 and DNMT3), miR-185 (targeting 






Following objectives were defined for this study: 
 
1. Use multiple high-throughput and low-throughput methods to investigate 
relative expression of microRNAs in two types of head and neck cancer 
samples: sinonasal and oropharyngeal carcinoma. 
 
2. Determine, if other epigenetic modifications such as DNA methylation are 
involved in regulation of studied microRNAs. 
 
 
3. Determine possible correlations between deregulated miRNAs 
and clinicopathological data of the patients by performing statistical 
analysis.  
 
4. Propose which miRNAs might be potentially utilized in the future as head 




6 Materials and Methods 
6.1 Sinonasal cancer patients and samples 
A total of 63 formalin-fixed, paraffin-embedded tissue samples from SSCC 
patients and normal control sinonasal tissue were analyzed in this study: 46 cancer 
cases samples and 17 control samples. Only tumors primarily originating from 
the nasal cavity, maxillary sinuses, and ethmoid complex were included, while 
no tumors were found in the frontal or sphenoid sinuses. The samples used 
as controls were 8 mucosal specimens from the nasal cavity and 9 from the maxillary 
sinus which were obtained from patients treated for a non-malignant diagnosis such 
as chronic rhinitis and sinusitis.   
Paraffin samples used in the study were obtained from Departments 
of Pathology of three University Hospitals in the Czech Republic (Hradec Kralove, 
Prague, Olomouc) and all malignancies were diagnosed between August 1995 
and August 2014. Carcinoma cases were classified according to the current World 
Health Organization (WHO) classification [82] and all the samples were reviewed 
by experienced head and neck pathologist. The study was approved by the Ethics 
Committee of University Hospital Hradec Kralove (201511 S27P).  
The tumors included exclusively squamous cell carcinomas (conventional, 
verrucous, papillary, basaloid, spindle cell, acantholytic, and adenosquamous). 
Vascular invasion, perineural spread, and microscopic findings in the surrounding 
mucosa were described.  
Data such as gender, age at the time of diagnosis, smoking history (non-smoker 
vs. ex-smoker vs. current smoker), occupation (high vs. low risk), tumor localization 
(nasal cavity, maxillary sinus and ethmoid complex), clinicopathological TNM were 
recorded for every patient. During the follow-up period (until February 2016) local 
recurrence, regional recurrence, distant recurrence, death and tumor-related death 
staging were documented (Table 2). The patients were treated with radical surgery, 
radiotherapy, and chemotherapy in various combinations. 
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31 67 % 




5 11 % 
> 50 41 89 % 
Smoking status (39) 
Smoker 
39 
22 56 % 




3 8 % 




21 47 % 
Maxillary sinus 22 49 % 




10 27 % 




36 80 % 




44 98 % 
M1 1 2 % 
Resection margin (46) 
Positive 
46 
38 83 % 




38 88 % 
G2, G3 5 12 % 
Vascular invasion (46) 
Yes 
46 
6 13 % 
No 40 87 % 
Perineural invasion (46) 
Yes 
46 
1 2 % 
No 45 98 % 
Local recurrence (41) 
Yes 
41 
15 37 % 
No 26 63 % 
Regional recurrence (40) 
Yes 
40 
3 8 % 
No 37 92 % 
Distant recurrence (39) 
Yes 
39 
3 8 % 
No 36 92 % 
HPV status (46) 
Negative 
46 
30 65 % 
Positive 16 35 % 
a Due to a few missing clinical data, sums do not always add up to the total 
number of patients. 
HPV, Human papilloma virus; pT, pathological characterization of primary 
tumor; pN, pathological classification of spread to regional lymph nodes; cM, 
presence of distant metastases. 
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HPV status was analyzed using HPV DNA in situ hybridization (ISH), HPV 
E6/E7 mRNA in situ hybridization (ISH), HPV DNA polymerase chain reaction 
(PCR) and typing, and HPV E6/E7 mRNA reverse transcription and polymerase 
chain reaction (RT-PCR). For the purpose of statistical analysis, a case was 
considered HPV positive if it was positive for HPV DNA ISH/PCR and/or HPV E6/E7 
mRNA ISH/PCR. For detailed information about HPV analysis see manuscript by 
Laco et al. [25]. Methods used to study miRNA expression and subsequent DNA 
methylation of miRNA genes in sinonasal cancer sample set are summed up 
in Figure 8 and Figure 9. 
Figure 8. Methodology used for squamous cell sinonasal cancer samples 
analysis.  
Total RNA was isolated from histologically verified FFPE samples of sinonasal 
cancer with miRNeasy FFPE Kit. cDNA synthesis was performed with 
TaqManTM Advanced miRNA cDNA Synthesis Kit and subsequent real-time 
PCR reaction with TaqManTM Fast Advanced Master Mix and selected 
TaqManTM Advanced miRNA Assays. Final data analysis was performed 
in STATISTICA software.  
 
Figure 9. Schematics of methodology used for DNA methylation analysis 
of miR-143 and miR-145 genes.  
DNA from samples was purified and bisulfite converted for subsequent 
methylation-specific high-resolution melting analysis (HRM). All data were 
statistically analyzed at the end of the experiment. 
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6.2 Oropharyngeal cancer patients 
Due to unique characteristics of the samples (tumors with corresponding 
metastases and healthy control tissue) different approaches to miRNA expression 
analysis as in SNC samples were used. Firstly, high-throughput analysis of miRNA 
expression such as miRNA microarray analysis (Figure 10) and small RNA 
sequencing (Figure 11) was used to select significantly dysregulated miRNAs 
within the sample set. Relative expression of pre-selected miRNAs was ultimately 
verified using real-time PCR analysis. 
 
Figure 10. Methodology used for miRNA microarray analysis and subsequent 
verification by RT-qPCR in OPSCC sample set.  
First, miRNA expression microarray from Agilent and subsequent 
bioinformatical analysis was used for preselection of significantly deregulated 





Figure 11. Methodology used for sRNA NGS analysis and subsequent 
verification by RT-qPCR in OPSCC sample set.  
First, sRNA NGS analysis on Illumina platform subsequent bioinformatical 
analysis was used for preselection of significantly deregulated miRNAs. 
The results were further validated by real-time PCR with preselected miRNA 
assays. 
As the primary aim of the study was the comparison of miRNA expression 
profiles between primary tumors, corresponding lymph node metastasis and control 
samples, only surgically treated oropharyngeal carcinoma patients with positive 
cervical lymph node metastases were enrolled in the study. A review of the surgical 
pathology files at The Fingerland Department of Pathology (University Hospital, 
Hradec Kralove, Czech Republic) identified a total of 73 patients who were 
diagnosed with metastasizing squamous cell carcinoma of the oropharynx between 
January 2000 and December 2014. Sufficient follow-up data were known for these 
patients and paraffin blocks were available for the analysis. All cases were reclassified 
by experienced head and neck pathologist according to the current WHO 
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Classification of Head and Neck Tumours [82]. The study was approved by the Ethics 
Committee of University Hospital Hradec Kralove (201611 S059 and 201711 S18P). 
For each patient, gender, age at the time of diagnosis, tumor localization 
(palatine tonsils and arches, root of the tongue, soft palate, and posterior wall of the 
oropharynx), tumor size, and pathological TNM staging (at the time of the study, 
7th edition was valid in the Czech Republic) [83] were recorded (Table 3). During the 
follow-up period (until March 2019) data on local recurrence, regional recurrence, 
distant recurrence, death, and tumor-related death were collected. All patients were 
treated by radical surgery with radiotherapy; chemotherapy was added 
in 22 patients. HPV status was examined at the Fingerland Department of pathology 
by p16 immunohistochemistry and HPV DNA detection by PCR for further 
information see manuscript Laco et al. [25]. 
All squamous cell carcinomas were further subclassified as non-keratinizing, 
non-keratinizing with maturation, or keratinizing according to the recently 
proposed criteria [84]. Only keratinizing carcinomas were graded as well, 
moderately, or poorly differentiated [82]. Vascular invasion, perineural spread, 
and status of resection margins (microscopically positive (R1) or negative (R0) were 
also noted. As we did not differentiate between blood and lymphatic vessel invasion, 
vascular invasion was present in all patients due to the presence of lymph node 
metastases (inclusion criterion). Apart from parameters necessary for pN staging, 
extranodal extension of metastasizing tumor cells was evaluated as well.  
As controls we used 44 samples of palatine tonsils resected due to chronic 
tonsillitis. Thus, a total of 190 formalin-fixed, paraffin-embedded samples 



















55 75 % 




25 34 % 




22 30 % 
Non-smoker 26 36 % 




21 29 % 




10 14 % 
Positive 63 86 % 
HPV p16 status 
Negative 
73 
14 19 % 




46 63 % 
Oropharynx 20 27 % 
Tonsillar fossa 4 6 % 





6 9 % 
Grade 3 1 1 % 
Non-keratinizing 46 63 % 
Non-keratinizing with 
maturation 




19 26 % 
T2 36 49 % 
T3 13 18 % 
T4 
T4a 2 3 % 




0 0 % 
N1 17 23 % 
N2 
N2a 27 37 % 
N2b 25 34 % 
N2c 1 1 % 




73 100 % 




10 14 % 





10 14 % 




11 15 % 




1 1 % 
No 72 99 % 
Regional recurrence Yes 73 4 5 % 
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8 11 % 
No 65 89 % 
HPV, Human papilloma virus; pT, pathological characterization of primary 
tumor; pN, pathological classification of spread to regional lymph nodes.  
6.3 Relative expression of microRNAs 
6.3.1 Total RNA isolation 
Two to four 5 µm thick sections were cut from FFPE tissue samples 
and deparaffinized using xylene and ethanol. Total RNA including miRNAs was 
isolated from FFPE tissue samples using two commercially available kits based 
on total RNA purification on silica columns purchased from Qiagen company 
(Hilden, Germany). miRNeasy FFPE Kit is designed to purify total RNA (including 
miRNAs) from FFPE samples and AllPrep DNA/RNA FFPE kit is designed to purify 
DNA and RNA (including short RNAs) from the same sample. All total RNA 
isolations were performed according to manufacturer’s protocol with small changes. 
The extracted RNA was ultimately eluted in 25 µl of RNase-free water. After 
the isolation, the samples were immediately processed or stored at -80 °C.  
6.3.2 Total RNA quality control 
Concentration and purity of isolated RNA was first assessed by NanoDrop 
ND 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) 
by measuring the optical density at 260 nm and 280 nm, A260/280 ratio 
and A260/230 ratio. Some of the samples were further analyzed on Qubit 
Fluorimeter (Thermo Fisher Scientific) using Qubit RNA HS Kit (Thermo Fisher 
Scientific), which provides accurate and selective method for the quantitation 
of low-abundance RNA samples. Total RNA quality (RIN) for subsequent miRNA 
microarray analysis was checked on Agilent Bioanalyzer (Agilent, Santa Clara, CA, 
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USA) using RNA 6000 Nano assay kit (Agilent). For the analysis 1 µl of each sample 
was used. 
6.3.3 miRNA microarray 
G3 Human miRNA Microarray, Release 21, 8×60K (Agilent) was used 
for high-throughput miRNome expression analysis of 40 selected samples of OPSCC 
(tumors, related metastases and controls). On one glass chip eight microarrays 
are printed with 60,000 oligonucleotide probes giving information about expression 
of 2,549 miRNAs based on miRbase release 21.0. Two glass arrays were hybridized 
at our workplace (Department of clinical biochemistry and diagnostics, University 
Hospital Hradec Králové, Molecular biology section) and then scanned on Agilent 
SureScan Microarray Scanner at HPST, s.r.o. (Písnická 372/20, Prague 4, Czech 
Republic). Analysis on following 3 glass arrays was performed at Central European 
Biosystems, s. r. o. (Pekařská 603/12, Prague 5, Czech Republic), where subsequent 
bioinformatics analysis of the scanned data was performed. 
All steps were performed according to manufacturer’s protocol with 100 ng 
of total RNA in the reaction. Briefly, Labeling Spike-In and Hybridization Spike-In 
controls were prepared to be added to the reaction as processing controls. Secondly, 
the samples were dephosphorylated by adding Calf Intestinal Phosphatase 
to the mixture and incubated at 37 °C. Thirdly, the samples were denatured 
by adding DMSO (dimethylsulfoxid) and incubation at 100 °C. Fourthly, Cyanine 
3-pCp dye was ligated to the sample by T4 RNA Ligase followed by purifying 
the labeled RNA using Micro Bio-Spin P-6 Gel column to remove DMSO 
and excessive free non-ligated Cyanine 3-pCp dye. After labeling reaction, 
the samples had to be completely dried up using vacuum concentrator with heater. 
Lastly, hybridization of the prepared samples to the glass array using 
the hybridization chamber and the hybridization gasket was performed. 
Hybridization oven was set to 55 °C for 20 hours. After hybridization the slides 
were washed with appropriate wash buffers and scanned on Agilent SureScan 
microarray scanner and unpacked by Feature extraction software.  
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Expression data were bioinformatically analyzed and divided into three groups 
(tumors × metastases × controls). The quantile normalization between arrays 
without background correction was performed at first. As the second step, the probe 
signal summarization to the level of individual miRNA genes was applied [85]. Both 
above steps were performed by the function rmaMicroRna from R package 
AgiMicroRna to all individual runs. The differentially expressed genes were 
identified by limma package. The batch effects were modeled as random effects 
during differential expression analysis. Differentially expressed miRNAs between 
these three groups were identified for further validation by qPCR. 
6.3.4 Small RNA Next generation sequencing 
For sRNA NGS library preparation NEBNext Small RNA Library Prep Kit 
for Illumina (New England Biolabs, Ipswich, MA, USA) was used. This kit contains 
the adaptors, primers, enzymes and buffers required to convert sRNAs (including 
miRNAs) into indexed libraries for next-generation sequencing on the Illumina 
platform. For NGS library preparation 40 samples of OPSCC were used (tumors, 
metastases and controls).  Starting amount of total RNA in the reaction was 
approximately 1 µg. All steps from the procedure were performed according 
to manufacturer’s protocol with minor modifications.  
Briefly, the first step of the procedure is to ligate 3’ SR Adaptor with addition 
of 3’ Ligation Enzyme Mix to the mixture. The second step of the workflow 
is to hybridize the Reverse Transcription primer, which is important to prevent 
adaptor-dimer formation.  The SR RT Primer hybridizes to the excess of 3´ SR 
Adaptor (that remains free after the 3´ ligation reaction) and transforms the single 
stranded DNA adaptor into a double-stranded DNA (dsDNA) molecule, which 
are not substrates for ligation mediated by T4 RNA Ligase 1 and therefore do not 
ligate to the 5´ SR Adaptor in the subsequent ligation step. This step needs to be 
immediately followed by Reverse transcription reaction using ProtoScript II Reverse 
Transcriptase. Next, PCR Amplification is performed using unique Index Primers 
(1-4) for Illumina to differentiate each sample after pooling.  
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At this step there are several different methods for performing size selection 
and pooling of the samples. Our NGS libraries were pooled based on concentrations 
of each sample determined by Qubit 3.0 using Qubit™ dsDNA HS Assay Kit 
(Invitrogen). Ultimately, three libraries based on concentration of the sample were 
prepared and concentrated using MinElute PCR Purification Kit. Each pooled library 
was run on 3% Agarose gel. The appropriate gel band (at approximately 140 bp, 
Figure 12) was cut out of the gel and the cDNA purified by NucleoSpin® Gel and PCR 
Clean-up Kit. Molarity of the prepared library was quantified using the KAPA library 
quantification assay (Kapa Biosystems, Wilmington, MA, USA) and a 2 nM or 4 nM 
library was prepared.  
 
Figure 12. Visualization of 3% agarose gel used for purification and size 
selection of pooled NGS libraries.  
Selected bands containing miRNAs (approximately 140 bp) are highlighted 
by blue boxes. 
Three runs of 1 x 50 single read NGS were performed on Illumina MiSeq 
instrument using MiSeq Reagent Kit v2 (50-cycles). The FASTAQ files were analyzed 
using Oasis 2.0 detection software [86]. sRNA detection module was used to obtain 
each miRNA counts by comparing the FASTAQ files to the reference genome and 
to perform quality control on NGS data. Differential expression (DE) analysis 
module was used to determine differentially expressed sRNAs (with elimination 
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of data outliers and low-quality samples) by comparing tumor samples with related 
metastasis samples and control samples. sRNA Classification module was used 
to detect novel sRNA biomarkers, their RNA targets and test for their functional 
enrichment. 
6.3.5   Quantitative real-time PCR 
The synthesis of cDNA was performed using TaqManTM Advanced miRNA cDNA 
Synthesis Kit with universal reverse transcription primers (Applied Biosystems, 
Foster City, CA, USA) according to manufacturer’s protocol with 8 – 10 ng of total 
RNA in the reaction. Real-time PCR was done with TaqManTM Fast Advanced Master 
Mix (Applied Biosystems) and specific TaqManTM Advanced miRNA Assays (Applied 
Biosystems) on Rotor-Gene Q (Qiagen). Hsa-miR-361-5p was used as endogenous 
control, because any other control miRNAs (such as Hsa-miR-939-5p were not stably 
expressed throughout all tissues). All steps were performed following 
the manufacturer’s protocol. Studied miRNAs were selected based on: 1) literary 
review dealing with deregulation of miRNAs in various types of head and neck 
cancer, 2) previous analysis by high-throughput methods such as Agilent miRNA 
microarray analysis and sRNA next-generation sequencing (Table 4). 
All reactions were performed in triplicates and each run contained no template 
control (NTC), reverse transcription control (without reverse-transcription enzyme) 
a calibrator (cDNA mixture for between runs normalization) prepared during cDNA 
synthesis reaction. Reaction volume was 10 µl with adding 2.5 µl of the sample to 7.5 
µl of TaqManTM Fast Advanced Master Mix TaqManTM Advanced miRNA Assay 
mixture. The reaction conditions were set according to the manufacturer’s protocol 
as follows: enzyme activation at 95 °C for 20 s followed by 40 cycles of denaturation 
at 95 °C for 3 s and annealing/extension at 60 °C for 30 s. Captured fluorescence data 
were analyzed in the Rotor-Gene Q Series Software. Relative expression of each 
miRNA was determined using the 2-ΔΔCt method [87] using in-house prepared 
Microsoft Excel template with expression levels of miR-361 used as endogenous 
control for data normalization. This workflow was chosen based on literature review 
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and manufacturer’s recommendation for endogenous controls listed in the user 
guide for TaqManTM Advanced miRNA Assays.  
Table 4. Information about TaqManTM Advanced miRNA Assays used for 













Hsa-let-7a-5p 478341_mir UGGAAGACUAGUGAUUUUGUUGU Literature  
Hsa-let-7d-5p 478439_mir AGAGGUAGUAGGUUGCAUAGUU Literature  
Hsa-miR-124-3p 477879_mir UAAGGCACGCGGUGAAUGCC  Literature 
Hsa-miR-137-3p 477904_mir UUAUUGCUUAAGAAUACGCGUAG Literature   
Hsa-miR-141-5p 478712_mir CAUCUUCCAGUACAGUGUUGGA Literature  
Hsa-miR-142-5p 477911_mir CAUAAAGUAGAAAGCACUACU  
miRNA 
microarray 
Hsa-miR-143-3p 477912_mir UGAGAUGAAGCACUGUAGCUC Literature  
Hsa-miR-145-5p 477916_mir GUCCAGUUUUCCCAGGAAUCCCU Literature  
Hsa-miR-146a-5p 478399_mir UGAGAACUGAAUUCCAUGGGUU Literature  
Hsa-miR-150-5p 477918_mir UCUCCCAACCCUUGUACCAGUG  
Small RNA 
NGS 
Hsa-miR-155-5p 483064_mir UUAAUGCUAAUCGUGAUAGGGGUU Literature  
Hsa-miR-196a-5p 478230_mir UAGGUAGUUUCAUGUUGUUGGG Literature  
Hsa-miR-200c-3p 478351_mir UAAUACUGCCGGGUAAUGAUGGA Literature  
Hsa-miR-200c-5p 478754_mir CGUCUUACCCAGCAGUGUUUGG Literature  
Hsa-miR-206 477968_mir UGGAAUGUAAGGAAGUGUGUGG  
miRNA 
microarray 
Hsa-miR-21-5p 477975_mir UAGCUUAUCAGACUGAUGUUGA Literature  
Hsa-miR-223-3p 477983_mir UGUCAGUUUGUCAAAUACCCCA Literature  










Hsa-miR-363-5p 478840_mir CGGGUGGAUCACGAUGCAAUUU Literature  
Hsa-miR-3656 480800_mir GGCGGGUGCGGGGGUGG  
miRNA 
microarray 
Hsa-miR-375-3p 478074_mir UUUGUUCGUUCGGCUCGCGUGA Literature 
Small RNA 
NGS 
Hsa-miR-4530 478918_mir CCCAGCAGGACGGGAGCG  
miRNA 
microarray 
Hsa-miR-484 478308_mir UCAGGCUCAGUCCCCUCCCGAU Literature  
hsa-miR-7-5p 478341_mir UGGAAGACUAGUGAUUUUGUUGU Literature  
Hsa-miR-939-5p* 478245_mir UGGAAGACUAGUGAUUUUGUUGU Literature  
Hsa-miR-9-3p 478211_mir AUAAAGCUAGAUAACCGAAAGU Literature  
Hsa-miR-9-5p 478214_mir UCUUUGGUUAUCUAGCUGUAUGA Literature  
Hsa-miR-99a-5p 478519_mir AACCCGUAGAUCCGAUCUUGUG Literature  
* Used as endogenous control assay 
50 
 
6.3.6 Statistical analysis 
All statistical analyses were performed using STATISTICA (data analysis 
software system) version 13 (TIBCO Software Inc., Tulsa, OK, USA). miRNA 
expression values were log-transformed to a normal distribution of data 
for parametric tests. Student's t-test was used to compare level of expression 
of miRNAs in tumor and non-tumor samples. The null hypothesis was based 
on theory that there was no difference between expression levels of studied 
microRNAs between tumor samples and control samples. For best diagnostic marker 
selection two web-based interactive tools were used: PanelComposer 
and CombiROC. CombiROC is a tool for validating biomarker candidates based 
on ROC (receiver operating characteristics) curves and the area under the ROC 
curve (AUC) using a logistic regression model. It is available online at: 
http://panelcomposer.proteomix.org/ [88]. CombiROC can determine optimal 
markers combination from different methods using sensitivity/specificity filters. 
It is freely available at: http://CombiROC.eu [89]. For the analysis data was log 
transformed. 
One-way analysis of variance (ANOVA) and regression analysis were used 
to analyze the correlation between expression levels of miRNAs and various 
clinicopathological features. The Kaplan-Maier method and Logrank test were used 
to determine overall survival rate and significance. All tests were two-tailed 
and P < 0.05 results were considered statistically significant. 
6.4 DNA methylation analysis 
6.4.1 DNA extraction and bisulfite conversion 
Genomic DNA was isolated from FFPE tissue samples of SSCC and control 
samples using QIAamp Genomic DNA Mini Kit or by QIAamp DNA FFPE Tissue Kit 
both supplied by Qiagen following manufacture’s protocol. Quality and purity 
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of extracted DNA was assessed by NanoDrop ND 1000 spectrophotometer 
and Qubit Fluorimeter (both supplied by Thermo Fisher Scientific). Sodium bisulfite 
treatment changes unmethylated cytosines into uracils, whereas 5-methylcytosines 
are resistant to this modification [90]. 500 ng of genomic DNA was treated with 
bisulfite using the EZ DNA Methylation-Gold™ Kit according to the manufacturer’s 
protocol (Zymo Research Corporation, Irvine, CA, USA). 
6.4.2 Methylation-sensitive high-resolution melting analysis 
HRM analysis is based on the fact that methylated and unmethylated, PCR 
products have different melting profiles when subjected to thermal denaturation. 
The methylation-sensitive high-resolution melting (MS-HRM) analysis procedure 
is based on the comparison of the melting profiles of PCR products from unknown 
samples with profiles specific for PCR products derived from methylated 
and unmethylated control DNAs. The procedure consists of PCR amplification 
of bisulfite-modified DNA with primers designed to proportionally amplify both 
methylated and unmethylated templates and subsequent high-resolution melting 
analysis of the PCR product [90]. 
Methylation analysis of miR-145 and miR-143 genes was performed 
to investigate, whether statistically significant downregulation of miR-145-5p might 
be linked to DNA methylation of the coding sequence. miR-145 and miR-145 are 
microRNAs that belong to the same cluster, so they are located very close to each 
other on the genome.  Primers for MS-HRM were designed in MethPrimer [91] 
to the promotor region of miR-143 and miR-145 genes and their mutual miR-143-3p 
and miR-145-5p host gene (CARMIN) (Table 5). The PCR products were designed 
to be shorter than 150 bp considering fragmentation of DNA obtained from FFPE 
samples. PCR amplification of all regions and subsequent HRM analysis was 
performed on Rotor-Gene Q (Qiagen).  
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Table 5. MS-HRM primer design information. 









































PCR was carried out in final volume of 10 µl. Volumes of each reactant for PCR 
of miR-145-1 and miR-143 amplicons were as follows: 1 µl of Reaction Buffer without 
MgCl2 (10×), 1 µl of MgCl2, 0.8 µl of dNTP mix for PCR (Takara Bio Inc., Kusatsu, 
Japan), 0.5 µl of each primer (Forward and Reverse, 10µM), 0.15 µl of SYTOTM 9 Dye 
(0.05 mM, Invitrogen), 0.125 µl of AmpliTaq Gold™ DNA Polymerase (All Applied 
Biosystems), 1 µl of bisulfite converted DNA sample and 4.93 µl of water. Cycling 
conditions are described in Table 6. Volumes of each reactant for PCR of miR-145-2 
and miR143/145 amplicon were as follows: 2.5 µl of 2× EpiTect HRM PCR Master Mix 
(Qiagen), 0.75 µl of each primer (Forward and Reverse, 10µM), 1 µl of bisulfite 
converted DNA sample and 2.5 µl of water. Cycling conditions are described in Table 
6. Each reaction run included an NTC and, a bisulfite-converted universal 
methylated and unmethylated DNA (Qiagen) and prepared standards containing 
10 % and 25 % of universal methylated DNA which served as a cut-off 




Table 6. Cycling conditions for HRM analysis. 
Stage 
Mir-145-1 and miR-143 
amplicon 








Initial denaturation 95°C 5 min 95°C 5 min 
Cycling 
40× 
Denaturation 95°C 20 s 95°C 10 s 
Annealing 60°C 30s 55°C 30 s 
Extension 72°C 30s 72°C 10 s 
Final Extension 72°C 5 min - - 
HRM analysis 
68-85°C 
ramping by 0.1°C 
2 s hold 
64-84°C  
ramping by 0.1°C 
2s hold 
Cool down 40°C 1 min 40°C 1 min 
6.4.3 Statistical analysis 
All statistical analyses were performed using STATISTICA (data analysis 
software system) version 13 (TIBCO Software Inc., Tulsa, OK, USA). The null 
hypothesis was based on theory 1) that there is no correlation between impaired 
miRNA expression deregulation and DNA methylation of promotor regions 
of miRNA genes.  
Basic descriptive statistics were adopted for the analysis: median, mean, and 95% 
confidence interval for continuous data, and absolute and relative frequencies 
for categorical data. The relationship between gene methylation and other 
independent factors was analyzed using the chi-square test, Fisher’s exact test, 






7.1 Differentially expressed miRNAs in sinonasal carcinoma 
7.1.1 Real-time PCR relative expression analysis 
In this study relative expression of 22 miRNAs (Table 4) was studied using 
TaqManTM Advanced real-time PCR approach based on literary review of miRNAs 
deregulated in squamous cell head and neck cancer in 46 SSCC samples and 17 
controls. As statistically significant upregulation was considered result with P < 0.05 
and Fold change (FC) > 2.0 and as downregulation was considered statistically 
significant, if P was < 0.05 and FC was < 2.0 compared to control sample expression. 
We detected significant upregulation of 6 miRNAs (Table 7): let-7a-5p, 
let-7d-5p, miR-196a-5p, miR-21-5p, miR-9-3-p, miR-9-5p (Figure 13) and significant 
down-regulation of 1 miRNA: miR-145-5p (Figure 14). 
Some of the miRNAs examined were deregulated, however the results were not 
statistically significant (such as miR-143-3p, miR-146a-5p, miR-155-5p, miR-137-3p, 
miR-223-3p, miR-454 and miR-99a-5p and miR-200c-3p).  
Expression levels of miR-141-5p, miR-200c-5p, miR-363-5p and miR-7-5p were 
below detectable level of the used method (real-time PCR with TaqManTM Advanced 
Assays). As a result, no reliable conclusions can be made regarding their expression 




Table 7. Relative expression of selected miRNAs in squamous cell sinonasal 
carcinoma detected by real-time PCR. 
Bold numbers show statistically significant results. 
microRNA P value FC 
Upregulated (Tumor versus Control) 
let-7a-5p < 0.001 5.65 
let-7d-5p < 0.001 3.93 
miR-143-3p 0.17 1.46 
miR-146a-5p 0.76 1.12 
miR-155-5p 0.27 1.46 
miR-196a-5p 0.0086 4.39 
miR-200c-3p 0.22 1.52 
miR-21-5p < 0.001 6.41 
miR-9-3p 0.017 3.07 
miR-9-5p < 0.001 6.80 
Downregulated (Tumor versus Control) 
miR-137-3p 0.98 -1.04 
miR-145-5p < 0.001 -2.78 
miR-223-3p 0.18 -1.71 
miR-484 0.33 -1.39 




Figure 13. Box plot of significantly upregulated miRNAs in SSCC samples.  
Horizontal line in the box marks median value and plus sign marks mean 
value. The box bounds Interquartile Range. Whiskers show Minimum 
and maximum values with outliers symbolized as dots. 
 
Figure 14. Box plot of significantly downregulated miRNA in SSCC samples.  
Horizontal line in the box marks median value and plus sign marks mean 
value. The box bounds Interquartile Range. Whiskers show Minimum 
and maximum values with outliers symbolized as dots. 
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All detected miRNA expression values were further analyzed to determine their 
diagnostic biomarker potential by web-based tools for evaluation of disease 
biomarker candidates: PanelComposer and CombiROC. With PanelComposer 
analysis the 5 miRNA panel (miR-21-5p, miR-9-5p, let-7d-5p, let-7a-5p and 
miR-196a-5p) was evaluated as the most successful diagnostic tool with P < 0.0001 
and area under curve 0.996 and confidence interval (CI) (0.995, 0.997). Analysis 
with CombiROC was used to discover to most effective combinations of miRNAs 
with one consisting of 4 miRNAs and the other consisting of 5 miRNAs. The first 
suggested panel consisted of miR-21-5p, let-7d, miR-155-5p and miR-223-3p 
(labelled as Combo V) with AUC = 0.971 (error rate = 0.095), when sensitivity (SE) 
was 0.87 and specificity (SP) was 1. Optimal cutoff for our samples was 0.803 (Figure 
15). The second selected combination consisted of 5 miRNAs: miR-21-5p, miR-9-3p, 
let-7d-5p, miR-155-5p and miR-223-3p (Combo VI). For this combination 
AUC = 0.977 (error rate = 0.048) with SE = 0.935 and SP = 1 and optimal cut-off 
value 0.708 (Figure 16). 
 
Figure 15. ROC curve for 4 miRNA panel for prediction of SSCC.  
Turquoise line represents ROC curve for miR-21-5p, let-7d, miR-155-5p 
and miR-223-3p panel. Yellow sun pictogram represents Optimal cut-off 
value. Diagonal line dots represent random guessing. 




Figure 16. ROC curve for 5 miRNA panel for prediction of SSCC.  
Turquoise line represents ROC curve for miR-21-5p, miR-9-3p, let-7d, 
miR-155-5p and miR-223-3p panel. Yellow sun pictogram represents Optimal 
cut-off value. Diagonal line dots represent random guessing. 
ROC, receiver operating characteristic. 
7.1.2 miRNA expression and patients’ survival 
Follow-up period of the patients ranged from 2 to 111 months with median value 
of 23 months. For the survival analysis we used Kaplan-Meier analysis to generate 
survival curves accompanied by Logrank test to obtain P value of prognostic 
significance of each miRNA expression regarding survival of patients. The patients 
were divided into two categories for each miRNA based on their expression levels. 
Only statistically significant outcomes of the analysis or data approaching statistical 
significance will be presented on following pages. 
7.1.2.1 miR-21 
The patients were divided into two categories based on quartile values. Samples 
with miR-21-5p relative expression in the highest quartile formed on group, whereas, 
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the rest of the samples were categorized as low expression group. The analysis 
showed that SCC patients with high expression of miR-21 (highest quartile) had 
impaired survival in comparison to other patients. The results were approaching  
statistical significance (P=0.0630) (Figure 17). 
 
Figure 17. Comparison of survival times of sinonasal SCC patients. 
Patients with high expression of miR-21 (highest quartile) had lower survival 
rate than patients with low expression. The difference is approaching 
statistical significance (Logrank test, P=0.0630). Vertical hatch marks show 
censored data.   
7.1.2.2 miR-9-5p 
The results suggested that patients with high expression of miR-9-5p (group 
of patients with expression levels in the top quartile) had better chance of survival 




Figure 18. Kaplan-Maier survival plot for miR-9-5p.  
Higher expression of miR-9-5p was detected for the patients with longer 
survival interval with statistical significance (P = 0.0264). Vertical hatch 
marks show censored data. 
7.1.2.3 let-7d-5p 
Our data subsequently showed that patients with low expression of let-7d had 
impaired survival in comparison to patients with higher expression of the same 
miRNA (based on lower quartile value). These results were statistically significant 




Figure 19. Kaplan-Maier survival plot for let-7d-5p.  
Lower expression of let-7d-5p was detected for the patients with shorter 
survival interval. The results are statistically significant with P value of 0.0417. 
Vertical hatch marks show censored data.  
7.1.2.4 miR-137-3p 
On the other hand, patients with higher expression of miR-137-3p had 
significantly impaired survival interval in comparison to the patients with lower 






Figure 20. Kaplan-Maier survival plot for miR-137-3p.  
Higher expression of miR-137-3p was detected for the patients with shorter 
survival interval. The results are statistically significant (P = 0.0278). Vertical 
hatch marks show censored data. 
7.1.3 Correlation with clinicopathological characteristics 
Overall clinicopathological data of the patients are summarized in Table 2. Age 
range of the patients at the time of diagnosis was between 27 and 82 years and 
median age was 65 years. During the follow-up period, 26/41 patients died, of whom 
11/39 due to the tumor. Control samples (n = 17) were acquired from 7 male and 10 
female patients. The youngest patient was 24 years old and the oldest one was 74 
years old while median age was 54 years. Using statistical analysis, we compared 
relative expression levels of examined miRNAs with clinicopathological 
characteristics described earlier (Table 8). All statistically significant results 
and results approaching statistical significance are described in the following text.
 
 




























Clinicopathological data P value 
Gender 
Male 













































































After performing statistical analysis, we concluded that all studied miRNAs apart 
from miR-223-3p correlated with at least one of the studied parameters. 
Deregulation mir-200c-3p and miR-155-5p showed a tendency to be related 
to the gender of the patients (mild upregulation of miR-200c-3p in female patients 
and downregulation in male patients and vice versa for mR-155-5p) with P = 0.072 
and P = 0.097 respectively. Let-7a was significantly more upregulated in patients 
older than 50 years of age in comparison to younger patients (P = 0.015).  Patients 
with recorder history of smoking or current smokers showed downregulation 
of miR-99a-5p, whereas nonsmokers had normal levels of this miRNA (P = 0.06). 
In samples of patients, where their occupation was assessed as a risk factor 
upregulation of miR-196a-5p and miR-9-3p was significantly higher in comparison 
to patients with safe occupations (P=0.0003 and P=0.031). Upregulation 
of miR-21-5p and let-7d tended to be higher in tumors occurring in maxillary sinus 
in comparison to tumors localized in nasal cavity (P = 0.026 and P = 0.078). 
Correspondently, miR-155-5p and miR-146a-5p expression was upregulated 
in samples originating in maxillary sinus, but mildly downregulated in samples 
from nasal cavity (P = 0.011 and P = 0.007). 
let-7a and miR-143-3p expression tended to be upregulated in lower cT stages 
of the disease (T1, T2) in comparison to later stages (T3, T4) (P = 0.077 and P= 0.08). 
miR-146a-5p and miR-155-5p were significantly more upregulated in patients 
with presence of nodal metastases (cN1-3) in comparison with patients without 
lymph node metastases (cN0). In patients with recorder presence of long distance 
metastases (cM0) expression of miR-143-3p tended to be downregulated 
in comparison to normal expression in patients with no distant metastases (cM0) 
with P = 0.08. Resection margin had no correlation with miRNA expression. 
miR-155-5p was upregulated in patients with high-grade (G2-3) stage tumors. 
In contrast, it was downregulated in low-grade (G1) tumor samples (P = 0.017). 
Vascular invasion was present in patients characterized by much higher expression 
of miR-9-3p (P = 0.013) and lower downregulation of miR-145-5 (P = 0.037). 
Moreover, perineural invasion was linked to much higher expression of miR-9-3p 
(P = 0.013) and significant downregulation of miR-99a-5p (P = 0.0055).  
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There were three types of recurrence events recorded during the follow-up 
period: local, regional and distant recurrence. Local recurrence was recorded 
in patients with lower upregulation of let-7a and let-7d (P = 0.016 and 0.025). 
Furthermore, with significant downregulation of miR-146a-5p (P = 0.015), 
then significant downregulation of miR-200c-3p (P = 0.0054) and finally significant 
upregulation of miR-137-3p (P = 0.045). On the other hand, regional recurrence was 
linked to significantly higher upregulation of miR-155-5p (P = 0.036), significantly 
lower upregulation of miR-9-5p (P = 0.045) and downregulation of miR-145-5p 
(P = 0.076). Distant recurrence correlations were limited due to low number 
of recorded cases. It seemed to be linked to miR-137-3p upregulation (P = 0.09).  
HPV infection presence seemed to have influence on expression of miR-145-5p, 
which was less downregulated in HPV positive patients (P = 0.019), miR-484, which 
was more downregulated in HPV+ patients and miR-99a-5p, which showed 
upregulation in HPV positive patients.  
7.1.4 Methylation analysis 
Methylation status of miR-145 gene, miR-143 gene and their host gene 
(miR-143/145) was investigated by methylation specific high-resolution melting 
analysis to determine, if the deregulation of the miRNAs is caused by DNA 
methylation regulation.  The cycling conditions and optimal master-mix 
composition was specifically optimized prior to the analysis of the samples. 
Methylation above 10 % (control containing 10 % of methylated DNA) was 




Figure 21. Methylation specific high-resolution melting analysis results. 
In the figure in the top left corner HRM the difference graph based on 10 % 
methylation control is displayed. In the bottom left corner Normalized HRM 
graph is displayed with melt curves in the right side of the figure. Red line 
is methylated control, yellow line is non-methylated control, blue line is 10 % 
methylated control purple line is 25 % methylated control and pink line 
is methylated sample. 
The results of the methylation analysis are inconclusive, due to low number 
of samples with successful amplification and subsequent DNA methylation analysis. 
The gene for miR-143 was methylated in 25/27 (92.6 %) of the sinonasal cancer 
samples. However, it was methylated in 7/7 (100 %) of the control samples. The first 
part if the miR-145 gene was methylated in 29/29 (100 %) of the samples and it was 
also methylated in 6/6 (100 %) of the control samples. The second part 
of the miR-145 gene was methylated in 16/28 (57.1 %) of the samples and it was 
methylated in 5/7 (71.4 %) of the control samples. The host gene miR-145/miR-143 
was methylated in 20/27 (74.1 %) of cancer samples and in 5/6 (83.3 %) of control 
samples. There was no significant change in methylation of the studied genes, when 
comparing tumor and control samples. Moreover, there was no significant 





7.2 Differentially expressed miRNAs in oropharyngeal carcinoma 
7.2.1 microRNA microarray 
In the first part of screening phase of the study Agilent miRNA microarray 
analysis and appropriate bioinformatical analysis were performed. We identified 
multiple miRNAs to be deregulated between tumor vs. control and metastasis vs. 
control sample sets and no miRNA to be significantly deregulated in comparison 
of tumor vs. metastasis samples.  
Analysis has identified 71 miRNAs to be deregulated in tumor samples as oppose 
to control samples. miRNAs were considered deregulated if FC > 2 or < -2 
and concurrently adjusted P < 0.05 (Figure 22). The most significantly upregulated 
miRNAs were miR-3656 (FC = 16.00 and P < 0.0001), miR-4530 (FC = 11.02 
and P < 0.0001), miR-4443 (FC = 10.36 and P = 0.0005) and miR-6088 (FC = 10.06 
and P < 0.0001). The most significantly downregulated miRNAs included 
miR-142-5p (FC = -14.79 and P = 0.009 and miR-223-3p with FC = -6,84 and P= 0.034 




Figure 22. Heat-map of differentially expressed miRNAs. 
The map includes color key and histogram of color representation. 
The clustering analysis shows two groups of samples: tumors in the middle 
of the heat-map and controls on the right side and left side of the map. 
KO, control samples; T, tumor samples. 
The second part of the study was to analyze if there are differentially expressed 
miRNAs when comparing their expression in metastasis samples and control 
samples. We have found 100 miRNAs to be significantly deregulated in metastasis 
samples (91 upregulated and 9 downregulated) (Figure 23). The most upregulated 
miRNAs included miR-3656 with FC = 14.51 and adjusted P < 0.0001, miR-4653-3p 
(FC = 11.08 and P = 0.0036) and miR-4530 (FC = 10.13 and P = 0.0001). The most 
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significantly downregulated miRNAs were  miR-142-5p with FC = -11.31 and adjusted 
P = 0.019 and miR-133b (FC = -8.54, P = 0.023) (Appendix Table 2). 
 
Figure 23. Heat-map of differentially expressed miRNAs. 
The figure includes color key and histogram of color representation. The 
clustering analysis shows two mixed groups of samples. Controls are grouped 
on the left side of the heat-map as opposed to metastases, which are grouped 
on the right side of the map with some outliers in the center. 
KO, control samples; M, metastasis samples. 
Thirdly, analysis of deregulated miRNAs between metastasis samples and tumor 
samples was performed (tumor samples were considered as controls). There were 
7 miRNAs deregulated (5 upregulated and 2 downregulated) (Figure 24). However, 
the deregulation was not statistically significant measured by adjusted P value. 
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The trend of upregulation was present for miR-133b (FC = 6.64 and P = 0.625) 
and for miR-206 (FC = 3.34 and P = 0.276). The trend of downregulation was present 
for miR-8485 (FC = -2.18, P = 0.995) and miR-150-5 (FC = -2.14, P = 0.995) 
(Appendix Table 3). 
 
Figure 24. Heat-map of differentially expressed miRNAs. 
The map includes color key and histogram of color representation. 
The clustering analysis shows two mixed groups of samples (tumors 
in the middle of the heat-map and metastases on the sides of the map). 
Although, no miRNAs were significantly deregulated, miRNAs with most 
significantly changed fold change were chosen for heat-map visualization. 
T, tumor samples; M, metastases. 
From all the results miR-3656 and miR-206 were selected for further validation 
second phase of the study – validation analysis by real-time PCR. miR-3656 was 
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selected based on its very significant deregulation in tumor and metastasis samples 
and comfortable expression levels throughout all the samples for subsequent 
analysis. miR-206 was selected, because it showed the most significant trend 
of deregulation between tumor and metastasis samples and it had stable levels 
of expression in all analyzed samples. 
7.2.2 Small RNA Next-generation sequencing 
In the second part of screening phase of the study next generation sequencing 
of sRNAs with focus on miRNAs was performed on MiSeq Illumina sequencer using 
NEBNext Small RNA Library Prep Kit. Initial quality control and mapping 
to reference genome (hg38) was performed in sRNA Detection module of Oasis 2.0. 
Samples with less than 90 % of trimmed reads and less than 40 % of uniquely 
mapped reads were considered as outliers. As a result, 33 samples (9 tumors, 12 
metastases and 11 control samples were used in subsequent analysis and 6 samples 
discarded as outliers or low-quality samples. Mean value of initial number of reads 
was 1,793,318 with mean value of 98 % of trimmed reads and 37 % of uniquely 




Figure 25. Heat-map of 30 the most expressed sequences in tumors, metastases 
and control samples. 
The heat-map visualizes 30 the most expressed sRNAs in the analyzed NGS 
counts based on regularized log transformation. The color key and histogram 
in the top left corner shows distribution of values and colors. 
Four different analyses were performed using Oasis 2.0 DE Analysis module (All 
three sets of samples of tumors corresponding metastases and control were 
compared with each other and together). Clustering of the three sets of samples is 
shown in Figure 26. Clustering analysis showed us one distinct group of control 




Figure 26. Clustering of individual samples based on sRNA expression profiles 
obtained by sRNA NGS.  
Blue dots represent control sample, green dots represent tumors and khaki 
dots represent metastases. PCA, Principal Component Analysis, PC, Principal 
Component. 
After differential expression analysis of tumor sample and control samples 
counts, the analysis provided 673 uniquely mapped reads (with minimum of 5 reads 
per sample). As a result, we have identified 673 sRNAs to be expressed 
in the samples. Of the total count of sRNAs 396 RNAs were identified as miRNAs, 
15 results were identified as novel miRNAs (miRNAs that have not been annotated 
in miRbase, 113 were identified as piRNAs, 109 as snoRNAs, 17 as snRNAs and 
23 as rRNAs. After selecting miRNA species from the analysis, 156 individual 
statistically deregulated miRNAs have been found, 52 of them were upregulated 
and 104 were downregulated (Appendix Table 4). The most upregulated miRNAs 
were miR-196a-5p (FC = 22.22 and adjusted P < 0.0001), miR-187-3p (FC = 11.26 and 
P < 0.0001), and miR-9-5p (FC = 8.11 and P < 0.0001). The most significantly 
downregulated miRNAs were miR-150-5p (FC = -9.87 and adjusted P = P < 0.0001), 






Figure 27. Heat-map of significantly deregulated sequences in tumor samples. 
The heat-map visualize 30 most significantly deregulated sequences 
in the analyzed NGS counts based on log2 fold change expression data 
(adjusted p value less than 0.1). The color key is in the top left corner of the 
figure. 
Differential expression analysis of metastases and control samples of NGS 
mapped counts revealed 690 uniquely mapped reads, which means that they were 
found in the reference sequence and had a minimum of 5 reads per sample. 
This corresponds with identifying 690 sRNAs among these samples. Of these RNAs, 
399 were uniquely mapped miRNAs, 15 were novel miRNAs, 118 were piRNAs, 
28 were rRNAs, 110 were snoRNAs and 20 were snRNAs. 
Focusing strictly on miRNA species revealed 71 significantly upregulated 
miRNAs and 75 significantly downregulated miRNAs (Appendix Table 5). The most 
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upregulated miRNAs in metastasis samples compared to control samples were 
miR-615-3p with FC = 19.93 and adjusted P value < 0.0001, miR-196-5p (FC = 19.34 
and P < 0.0001) and miR-9-5p (FC = 11.23 and P < 0.0001). The most downregulating 
miRNAs were miR-150-5p (FC = -9.18, P < 0.0001), miR-766-3p (FC = -5.90 
and P < 0.0001) and miR-142-5p (FC = -5.64, P < 0.0001) (Figure 28).  
 
Figure 28. Heat-map of significantly deregulated sequences in tumor samples. 
The heat-map visualize 30 most significantly deregulated sequences 
in the analyzed NGS counts of metastasis data based on log2 fold change 
expression data (adjusted p value less than 0.1). The color key is in the top left 
corner of the figure. 
Using Oasis 2.0 differential expression analysis of tumor samples versus 
metastasis samples (tumor samples were marked as control group and metastasis 
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samples were marked as treatment group for the analysis) we have identified 700 
uniquely mapped NGS reads. Consequently, we have identified 700 small RNA 
species to be captured at minimum of 5 reads per sample. Out of 700 sRNAs, 393 
were miRNAs and 16 were novel miRNAs. From the other sRNAs species 125 piRNAs 
were present, 30 rRNAs, 115 snoRNAs and 21 snRNAs. After other than miRNA small 
RNA species filtering, we have found 9 miRNAs to be significantly deregulated 
(Appendix Table 6). Significantly upregulated miRNAs were: miR-514a-3p 
with FC = 2.89 and adjusted P value = 0.0350 and miR-218-5p with FC = 2.42 
and P = 0.0245. The most significantly downregulated miRNAs were: miR-375 
(FC = -8.12 and P < 0.0001), miR-1-3p (FC = -4.46 and P = 0.0018) and miR-4532 
(FC = -3.88 and P = 0.0015) (Figure 29).  
 
Figure 29. Heat-map of significantly deregulated sequences in metastases 
versus tumor samples. 
The heat-map visualize the most significantly deregulated sequences 
in the analyzed NGS counts of metastasis data based on log2 fold change 
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expression data (adjusted p value less than 0.1). The color key is in the top left 
corner of the figure. 
After evaluation of all small RNAs NGS data two miRNAs were selected 
for further validation by real-time PCR: miR-375-3p and miR-150-5p. miR-375-3p 
(previously known as miR-375) was selected based on its significant deregulation 
in metastasis samples compared to tumor samples and the expression was enough 
for further analysis. miR-375 was also validated as the best biomarker for tumors 
and metastases differentiation using Classification Analysis module of Oasis 2.0 
with feature importance 1.049. On the other hand, miR-150-5p was selected 
for its significant downregulation in both tumor and metastasis samples. 
This miRNA was also among the selected as potentially good biomarker of tumor 
samples vs. control samples differentiation by Classification Analysis by Oasis 2.0 
with feature importance 0.298. 
7.2.3 Real-time PCR evaluation analysis 
7.2.3.1 Relative expression verification analysis 
In the second phase of the study, differentially expressed miRNAs 
in oropharyngeal cancer samples and corresponding metastases were analyzed using 
real-time PCR TaqMan Advanced approach. miRNAs for verification analysis were 
selected based on Agilent miRNA microarray results and small RNA NGS Illumina 
sequencing. Four miRNAs were selected to be suitable for phase two of the study: 
miR-3656, miR-206, miR-150-5p and miR-375-3p. 
The analysis confirmed that miR-3656 was significantly upregulated in tumor 
samples (FC = 6.56 and P = 0.0006) and less but significantly upregulated 
in metastasis samples (FC = 3.04 and P = 0.012) compared to control samples. 
Moreover, deregulation between the three sets of samples was significant according 
to ANOVA (P = 0.0012). Correspondently, miR-150-5p was significantly 
downregulated in tumor samples (FC = -14.75 and P < 0.0001) and significantly 
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downregulated in metastasis samples compared to control samples (FC = -8.94 
and P < 0.0001). Moreover, ANOVA confirmed statistical significance in expression 
between all three sets of samples (P < 0.0001) and there was difference in expression 
between metastases and tumors (FC = 1.30 and  P = 0.049) (Figure 30).  
 
Figure 30. Deregulated miRNAs in the second phase of the study. 
miR-3656 and miR-150-5p were confirmed to be significantly deregulated 
in tumor and metastasis samples by real-time PCR analysis with TaqManTM 
Advanced Assays. Whiskers show Minimum and maximum values 
with outliers symbolized as dots and extremes symbolized as asterisks. 
On the other hand, miR-206 was significantly downregulated in metastasis 
samples compared to tumor samples (FC = -39.99 and P < 0.0001). It was 
significantly upregulated in tumor samples compared to controls (FC = 10.93 
and P < 0.0001). In contrast, there was a significant downregulation in metastasis 
samples compared to control samples (FC = -3.93 and P = 0.0061). Finally, there was 
a trend of downregulation of miR-375 in metastasis samples compared to tumor 
samples (FC = -2.45 and P = 0.146). Even though, the deregulation was statistically 
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significant according to small RNA NGS data, we were unable to confirm 
the statistically significant results using real-time PCR analysis (Figure 31). 
  
Figure 31. Deregulated miRNAs in the second phase of the study. 
miR-206 and miR-375-3p were confirmed to be deregulated in metastasis 
samples compared to tumor samples by real-time PCR analysis 
with TaqManTM Advanced Assays. However, only the results for miR-206 
were significantly deregulated. Whiskers show Minimum and maximum 
values with outliers symbolized as dots and extremes symbolized as asterisks. 
The four selected miRNAs were further analyzed to determine their diagnostic 
biomarker potential using PanelComposer and CombiROC web-based tools. Tumor 
and metastasis samples were considered as positive samples and control samples 
were considered as negative samples. According to PanelComposer analysis 
miR-150-5p is the best diagnostic biomarker for oropharyngeal cancer 
with AUC = 0.934, confidence interval (0.934, 0.935) and P < 0.0001. The most 
efficient panel is: miR-3656, miR-206 and miR-150-5p with AUC = 0.908, 
CI = (0.908, 0.909) and P < 0.0001. The best miRNA panel suggested by CombiROC 
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tool is miR-3656 combined with miR-150-5p and miR-375-3p with AUC = 0.948 
(ER = 0.084), SE = 0.922, SP = 0.09 and optimal cut-off value 0.705 (Figure 32). 
 
Figure 32. ROC curve for 3 miRNA panel for prediction of OPSCC.  
Turquoise line represents ROC curve for miR-3656, miR-150-5p 
and miR-375-3p panel. Yellow sun pictogram represents Optimal cut-off 
value. Diagonal line dots represent random guessing. 
ROC, receiver operating characteristic 
7.2.3.2 miRNA expression and patients’ survival 
Follow-up period of the patients ranged from 3 to 180 months (until March 2019) 
and median value was 82 months. For the survival analysis we used Kaplan-Meier 
analysis to generate survival curves accompanied by Logrank test to obtain P value 
of prognostic significance of each miRNA expression regarding survival 
of the patients. The patients were divided into two categories for each miRNA based 
on their expression levels. Only expression of miR-150-5p was associated with longer 
survival intervals. 
The expression data were divided into two categories independently for tumor 
samples and metastasis samples based on median values. The tumor samples 
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with lower expression of miR-150-5p were grouped together (P = 0.0124) (Figure 33) 
and metastasis samples with lower expression of miR-150-5p were grouped into one 
category (P = 0.0192) (Figure 34). 
 
Figure 33. Comparison of survival times of OPSCC patients based 
on miR-150-5p expression in primary tumors. 
Patients with lower expression of miR-150-5p (based on median value) had 
impaired survival in comparison to higher expression group. The difference 
is statistically significant with P = 0.0124 (Logrank test). Vertical hatch marks 




Figure 34. Comparison of survival times of OPSCC patients based 
on miR-150-5p expression in metastases. 
Patients with lower expression of miR-150-5p showed impaired survival 
in comparison to higher expression group. The difference is statistically 
significant with P = 0.0192 (Logrank test). Vertical hatch marks show 
censored data. 
7.2.3.3 Correlation with clinicopathological characteristics 
Overall clinicopathological data of the oropharyngeal cancer patients 
are summarized in Table 3. Age range of the patients at the time of diagnosis was 
between 41 and 80 years and median age was 58 years of age. During the follow-up 
period 31/83 patients died, of whom 10/31 directly due to the tumor. Control samples 
were acquired from patients with non-malignant diagnosis treated for chronic 
tonsillitis.  All known clinicopathological data was compared to relative expression 
of four miRNAs that were part of second phase of the study (Table 9). All statistically 
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significant results and results approaching statistical significance are described 
in the following text. 
Table 9. Correlations of miRNA expression with clinicopathological data 
in OPSCC samples. 
Clinicopathological Characteristics miR-3656 miR-206 miR-150-5p miR-375-3p 
Gender 
Male 




















0.74 0.72 0.57 0.31 
Oropharynx 
Tonsillar fossa 
Base of tongue 
Typing 
Keratinizing 
0.18 0.39 0.010 0.34 
Non-keratinizing 
pT 
T1 – T2 
0.061 0.09 0.0016 0.103 
T3 – T4 
pN 
N1 
0.88 0.80 0.028 0.99 
N2 – N3 
Perineural invasion 
Yes 








0.60 0.78 0.053 0.99 
No 
Statistically significant results and results approaching statistical significance 
and are marked in bold. 
All the miRNAs selected for second phase of the study correlated with at least 
one of the tracked clinicopathological characteristics. miR-3656 correlated with size 
and extension of the primary tumor (pT), while the less extensive tumors (T1 – T2) 
had less prominent downregulation of the miRNA than more extensive tumors 
(T3 – T4) with P = 0.0016. Concurrently, the more extensive tumors had high 
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upregulation of miR-206 in comparison to less extensive tumors with results 
approaching statistical significance (P = 0.09).  
On the other hand, miR-150-5p correlated with several recorded parameters. 
The trend of higher downregulation of miR-150-5p in HPV positive samples was 
observed with P = 0.071. Keratinizing tumors had lower expression of miR-150-5p 
than non-keratinizing tumors (P = 0.010). Size and extension of the tumor also 
correlated with miR-150-5p expression, when lower expression of the miRNA was 
present T3 – T4 stage tumors (P = 0.0016). Moreover, downregulation of miR-150-5p 
was less prominent in tumors with higher regional lymph nodes metastases 
involvement (N2 – N3) (P = 0.028). miR-150-5p expression also correlated with 
recurrence (three types of recurrence were recorded: local, regional and distant) 
of the disease and the downregulation was more significant in patients 
with recorded follow-up recurrence (P = 0.053). Finally, miR-375-3p correlated 





Sinonasal and oropharyngeal cancers as well as other tumors arising from 
anatomically complex head and neck area are characterized by difficult treatment, 
poor prognosis and low survival rate [11]. The accumulation of aberrant epigenetics 
events (such as posttranscriptional deregulation by miRNAs and DNA methylation) 
can influence head and neck cancer pathology [92]. microRNAs have been 
recognized as key molecules in cancer development and progression in various types 
of tumors. They have been established as promising prognostic cancer biomarkers 
due to their resistance to degradation in many tissue types (including FFPE tissues) 
and various body fluids (such as plasma, serum, urine, or saliva). The amount 
of research papers published that are focused on miRNA research grows rapidly 
each year [93; 94].  
Up- or down-regulation of miRNAs occurs usually in the same direction across 
most of the cancer subtypes. For example, miR-21 is upregulated in almost all human 
cancer types   and its oncogenic effect has been extensively described [95-97].  
Number of studies focused on miRNA expression in sinonasal cancer has been 
limited. Ogawa et al. [71] studied correlation between downregulation of miR-34a 
and resistance to CDDP treatment. The downregulation of miR-34a in SSCC 
was further confirmed by Zhao and Wang [72] and the further associated it with 
poor prognosis of the patients. HPV positive OPSCC is currently the hot topic 
of oropharyngeal cancer research. Deregulation of various miRNAs (such as miR-31, 
miR-24, miR-146a, etc.) has been previously described [75]. 
In the current study, we investigated relative expression of several preselected 
miRNAs and the relationship between their expression and clinicopathological 
characteristics of the patients. miRNAs of interest for this study were selected based 
on literary review focused on other types of squamous cell head and neck cancer 
(sinonasal cancer study) and high-throughput miRNA expression methods 
in the phase I of the oropharyngeal cancer study. 
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8.1 Differentially expressed miRNAs in sinonasal carcinoma 
Using real-time assay-based approach for relative expression analysis of miRNAs 
followed by 2-ΔΔCt analysis has been a gold standard for miRNA expression studies 
for decades. The main reasons are unmatched specificity, simplicity 
of the procedures and affordable price of the chemistry [98]. However, the main 
downside of the method is limitation in number of miRNAs that can be detected 
during one analysis.  
Using relatively new miRNA detection design by TaqManTM Advanced Assays 
we were able to detect relative expression of 22 miRNAs in several steps of the SNC 
study in a span of three years. cDNA from a single tube of obtained from one step 
synthesis by TaqManTM Advanced Synthesis Kit with non-specific miRNA 
reverse-transcription primers was used as an input material for all real-time PCR 
reactions. With Advanced TaqMan technology, we were able to study both 5p and 3p 
variants of the same miRNA, because of the sequence specificity of the pre-designed 
Assays [99]. All pre-designed assays were mapped to the newest version of miRBase 
(v22). 
Assay selection for the SNC study was based on literary review of previously 
studied miRNAs. However, because miRNA expression studies in SNC are rare, 
assays were predominantly selected based on previously published research on head 
and neck squamous cell cancer. As a result, not all selected miRNAs were expressed 
or deregulated (according to the criteria of P value < 0.05 and Fold change 
more significant than 2) in our set of sinonasal cancer samples.   
Moreover, for some miRNAs only one strand of mature miRNA was expressed. 
In our experiments, miR-200c-3p did not reach the detection limit of real-time PCR 
analysis. However, miR-200c-5p strand of the miRNA was abundantly expressed in 
SNC and control tissue, even though, the upregulation did not reach the statistical 
significance. These data correlate with results of Kawakubo-Yasukochi et al., who 
reported miR-200-3p involvement in invasiveness of oral squamous cell carcinoma 
[100]. On the other hand, in case of miR-9 both mature strands (5p and 3p) were 
upregulated in the samples. Our findings about the expression of mature forms 
88 
 
of miR-200 and miR-9 support arguments that expression of both strands (guide 
and passenger) of one miRNA can play different biological roles in cancer pathology 
[101]. 
One way of increasing specificity of miRNAs as diagnostic biomarkers 
of the disease is designing a panel of multiple miRNAs. After ROC analysis 
we suggest two panels of studied miRNAs for this purpose with AUC larger 
than 0.95: 4 miRNA panel: miR-21-5p, let-7d, miR-155-5p and miR-223-3p and 5 
miRNA panel: miR-21-5p, miR-9-3p, let-7d-5p, miR-155-5p and miR-223-3p. 
The tissue specificity of the miRNA panel needs to be further confirmed in different 
tumor types. 
8.1.1 miR-9 
Our experiment shows that both 3’ and 5’ miR-9 strands are abundantly 
expressed and upregulated in SSCC samples in comparison to controls. 
In concordance with our results Salazar et al. [102] were able to find upregulation 
of miR-9 in small amounts of saliva of HNSCC patients.  
The upregulation was more significant for the 5’ strand of miR-9 with fold 
change of 6.80. 3’ form of the same miRNA was significantly upregulated as well 
with fold change of 3.07. More importantly, we detected significantly longer survival 
interval in patients with higher expression of miR-9-5p (P = 0.0264). Citron et al. 
[103] identified upregulation of miR-9 in patients with head and neck squamous cell 
carcinoma and also concluded that this particular miRNA is an important mediator 
of recurrence formation in HNSCC by regulating EMT process. Similarly, Yu et al. 
[104] reported that nicotine treated cells had significantly higher expression 
of miR-9 leading to promotion of metastatic processes by E-cadherin repression. 
Their conclusions support our findings of correlation between vascular invasion 
and upregulation of miR-9-3p and, consecutively, of correlation between perineural 
invasion and the same microRNA strand. Moreover, our results showed relationship 
between regional recurrence of SSCC recorded in our patients and relative 
expression of miR-9-5p. We have not found any correlation between miR-9 
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expression and presence of HPV in our samples. Even though Vojtechova et al. [105] 
concluded that miR-9-5p is specific for HPV positive tonsillar tumors. 
8.1.2 miR-21 
miR-21 is the most commonly deregulated miRNA across diseases and tissue 
types. Survival analysis of our samples showed that SSCC patients with high 
expression of miR-21 had impaired survival approaching statistical significance 
in comparison to patients with lower upregulation of miR-21.  Relationship between 
patients’ survival time and level of miR-21 upregulation was observed by many other 
authors studying head and neck cancerous tissue such as Avissar et al. [106] and Ko 
et al. [107]. Moreover, we observed trends towards higher levels of miR-21 expression 
in samples from sinonasal cancer patients in advanced stages of the disease. 
However, the results were not statistically significant, or they had limited statistical 
power due to low number of samples. The same trend was previously observed by Hu 
et al. [108] in oral SCC. Mir-21 limitation as a biomarker is low tissue and disease 
specificity. It has been reported to be involved in many different pathological 
processes in the human body [109]. 
8.1.3 miR-143-3p and miR-145-5p and their regulation 
Both miRNAs have been reported to be deregulated in various types of head 
and neck cancer. It was proposed that miR-143 functions in the apoptosis, invasion 
and migration processes of head and neck cancer [110; 111]. We did not find 
any significant deregulation of miR-143-3p in our SSCC samples in comparison 
to control samples, even though they have been abundantly expressed in the studied 
tissue.   
Even though, miR-143 and miR-145 are coded next to each other on the genome, 
their expression was dissimilar in our samples which we thought might have been 
attributed to methylation of their coding genes, so we further investigated 
the methylation status by MS-HRM analysis. miR-145 and miR-143 are expressed 
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together by transcription of their host gene CARMIN and then cleaved 
by DGCR8/Drosha into the two individual pre-miRs [112]. However, the presence 
of individual promoters for both miRNAs has also been reported. There 
was no difference of methylation in the promotor regions of the genes. 
The hypermethylation of promotor CpG islands was high not only in sinonasal 
patients’ samples, also control samples were hypermethylated. Our results indicate 
that the expression of miR-143 is not regulated by DNA methylation or that 
our primers did not span the right regulation region of the gene. 
8.1.4 miR-155-5p 
MiR-155-5p have been found to be deregulated in HNSCC and its oncogenic role 
in development of various types of head and neck cancer and the ability to promote 
metastatic processes has been reported [113]. Although we did not find any 
statistically significant differences in expression of miR-155-5p between carcinoma 
samples and control samples, we were able to identify several correlations between 
miR-155-5p expression and several clinicopathological data suggesting the idea 
of miR-155-5p relevance as prognostic biomarker of HNSCC.  
8.1.5 Let-7d and Let-7a 
From our experiments it seems that microRNA let-7a and let-7d are upregulated 
in SSCC samples in comparison to sinonasal control tissue. Members of miRNA let-7 
family are generally considered to be upregulated in aggressive tumors of head 
and neck [114]. According to our data analysis we concluded that the patients with 
extremely high expression of let-7d had better chance of survival than the patients 
with lower upregulation of the same miRNA. It implies that lower levels of let-7 
are associated with impaired survival in HNSCC. 
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8.1.6 Other miRNAs 
miR-146a-5p was not significantly deregulated in our samples as was suggested 
by Yang et al. [115] in chronic rhinitis. However, we have found the miRNA 
to be locally downregulated in nasal cavity. Our results also suggest its’ involvement 
in lymph node metastases formation, as suggested by Scapoli et al [116].  
miR-196a-5p was significantly upregulated in our samples, which corresponds 
with results of Maruyama et al. [117]. It was also upregulated in patients 
with occupational exposure to cancerogenic substances, which implies its role 
in sinonasal inflammation and subsequent tumorigenesis. 
MiR-137 has been reported to be downregulated in HNSCC and to have a role 
in suppression of oncogenes [118]. We have not found miR-137-3p to be deregulated 
in our set of samples. We were able to associate higher expression of miR-137-3p 
with impaired survival of the patients with SSCC and we found correlation between 
local recurrence of the sinonasal tumors and higher expression of miR-137-3p.  
Reports of deregulation of miR-99a in head and neck cancer have been 
published, which we could not confirm in SNC. However, we have found 
downregulation of miR-99a in patients with recorded history of smoking, which 
might be connected to possible suggested regulation of miR-99a DNA damage 
response [119]. 
8.2 Differentially expressed miRNAs in oropharyngeal carcinoma 
Malignancies localized in the oropharyngeal area are typically characterized 
by small primary tumor occurrence and significant lymph node metastases, which 
might by diagnosed prior to primary tumor [14]. Therefore, in this study 
we characterized relative expression of miRNAs not only in primary OPSCC tumor 
tissue, but also in related metastatic tissue of the patients. Expression of miRNAs 
was then compared to set of non-malignant control samples from the area 
of oropharynx. This study design enabled us to characterize differences of miRNA 
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expression in cells that have metastatic potential and went through metastatic 
process. 
The incidence of oropharyngeal cancer as oppose to other types of head and neck 
cancers (such as sinonasal cancer) has a rising tendency. Growing frequency of HPV 
infection in (especially Western) population is considered responsible for this 
phenomenon. Most of the oropharyngeal cancers are nowadays caused by ongoing 
high-risk HPV infection of the area. Oropharynx is more prone to HPV related 
tumors thanks to its immune system component. Although, HPV positive OPSCC 
tumors tend to respond to treatment better than HPV negative tumors, it is still 
a serious disease with impact on the life of the patient. Most of the current research 
regarding cancer of the area is for obvious reasons focused on studying HPV positive 
tumors [34]. In this study, we included HPV positive and HPV negative samples into 
the cohort to investigate their miRNA related differences.  
In oropharyngeal cancer several epigenetic (focused on miRNAs) studies has 
been published [74; 75]. For this reason, we selected different approach 
in the OPSCC study than in the SSCC study, so we did not select studied miRNAs 
based on literary review. The first phase of the study was preselection of interestingly 
deregulated miRNAs using high-throughput miRNA expression methods. 
The second phase of the study was designed to verify the changes in expression 
of pre-selected miRNAs by real-time PCR. High-throughput methods for miRNome 
profiling involve microarrays, real-time PCR based arrays and next-generation 
sequencing [120]. We have selected two of these methods (microarray and NGS) 
to be used in this study based on the premise that we can use them to investigate all 
miRNAs expressed in the sample. Agilent miRNA microarray and NebNext Small 
RNA technology was used due to high sensitivity, up to date content from the most 
current data on miRBase and availability of the technology at our laboratory. 
Moreover, these methods target mature miRNAs (as oppose to stem loop sequence) 
so we can investigate relative expression of both 5’ and 3’ mature miRNA strands. 
NGS sequencing of small RNA is a method also used for novel miRNA 
identification studies. However, for this purpose ~10 million NGS reads per sample 
are required. Furthermore, with appropriate bioinformatics tools small RNA NGS 
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analysis allows differentiation between various isoforms of the same miRNA 
(isomiRs), which are variants of the same miRNA that differ from canonical mature 
sequence. isomiRs could be eventually used as more specific biomarkers for various 
types of cancer [121; 122]. Even though, analysis of our data in Oasis 2 software 
identified several novel miRNAs and potential isomiRs, but sequencing was not deep 
enough to draw any reliable conclusions and it was not aim of the current study. 
8.2.1 miR-150-5p 
miR-150-5p was selected for its significant downregulation in both tumor and 
metastasis samples. This miRNA was also among the selected as potentially good 
biomarker of tumor samples vs. control samples differentiation by Oasis 2.0 
Classification Analysis. In concordance, comparison of results obtained 
from microarray data confirms significant downregulation of the miRNA in tumor 
samples and less prominent downregulation in metastases samples. Real-time PCR 
analysis was in complete agreement with first phase of the study results 
and confirmed downregulation of miR-150-5p.  
Downregulation of miR-150-5p in head and neck squamous cell carcinoma was 
detected by Koshizuka et al. [123], who also reported contribution of the 
downregulation of miR-150 to the aggressiveness of the tumor. In concordance, 
we have found that patients with very low expression of miR-150-5p had impaired 
survival in comparison to patients with less significant downregulation of the 
miRNA. The same results are valid for tumor samples and for metastasis samples 
of the same patients. This miRNA was also less expressed in HPV positive tumors 
and in keratinizing tumors. Moreover, more advanced stages of the disease 
and recurrent tumors parameters correlated with very low expression of the disease. 
All these results suggest that miR-150-5p could be used as a prognostic biomarker 
of the oropharyngeal cancer. Correspondently, it was evaluated as the best 
biomarker by PanelComposer and CombiROC analysis (with miR-3656 and 
miR-375-3p). Downregulation of miR-150-5p could help with characterization of the 
94 
 
lymph node mestasasis and original subsite of the tumor. Further analyses need 
to be performed to determine specificity of the miRNA for studied tissue. 
8.2.2 miR-206 
From the results of miRNA microarray analysis, we can see that many miRNAs 
are upregulated in the tumor samples and metastasis samples with high statistical 
significance. Most of the upregulated miRNAs in tumor samples are also upregulated 
in metastasis samples with less significant fold change value. miR-206 was according 
to microarray not deregulated in tumors but downregulated in metastases. 
Moreover, microarray analysis also shows that this miRNA is downregulated 
in metastasis samples compared to tumor samples. NGS results shows upregulation 
of miR-206 in tumor samples, downregulation of miR-206 in metastases 
and downregulation of miR-206 in metastases versus tumors. For these reasons 
miR-206 was selected for second phase of the study. miR-206 expression was further 
validated using real-time PCR, which fully confirmed the results obtained from NGS 
and trends suggested in miRNA microarray. With discrepancy to our results, Liu 
et al. [124] reported downregulation of miR-206 in head and neck squamous cell 
carcinoma samples. However, in epithelial ovarian cancer, downregulation 
of miR-206 was associated with metastasis and poor prognosis [125]. 
8.2.3 miR-3656 
This miRNA was selected for further validation based on its very significant 
deregulation in tumor and metastasis samples according to microarray analysis. 
It was the most significantly upregulated miRNA based on fold change value not 
only in tumors but also in metastases. However, this trend was not observed in NGS 
analysis were miR-3656 was slightly upregulated only in tumor samples and not 
in metastasis samples. Eventually, real-time PCR verification of miR-3656 expression 
confirmed the results of miRNA microarray and showed that miR-3656 
is upregulated in OPSCC samples. One of the reasons for disparity between 
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expression results of miR-3656 might be the fact, that stem loop sequence 
of miR-3656 was excluded from the newest version of miRBase (version 22). 
In the newest version of the database only a mature sequence of the miRNA 
is annotated, because the mature sequence might derive from annotated 28S rRNA 
sequences. Hence, this update of the database might cause differences in results, 
because miRNA microarray (based on miRBase v.21) was done prior to NGS analysis 
(aligned to miRBase 22) and real-time PCR assays was purchased prior to version 22 
database release and it is no longer available under the same catalogue number [126]. 
Due to complicated about the nomenclature, miR-3656 and rarity of the miRNA, 
there are not many studies that would focus on miR-3656 expression. However, 
it has been found upregulated in breast cancer [127] and in pancreatic cancer [128]. 
8.2.4 miR-375-3p 
miR-375-3p (previously known as miR-375 in previous version of miRBase) 
was selected based on its significant deregulation in metastasis samples compared 
to tumor samples in the same manner as mir-206. The main reason for selection 
of this miRNA were results obtained from small RNA NGS data, were it was 
suggested as the most valuable biomarker for distinction of metastases and tumors. 
According to NGS results miR-375 was significantly upregulated in tumors 
and significantly downregulated in metastases. In miRNA microarray data there was 
no deregulation detected in any of the evaluations. On the other hand, real-time 
PCR showed a trend of miR-375 downregulation on metastases compared to tumors 
with significant fold change. However, the p value was not significant due to high 
variability of results within the sample set. As a result, we were not able to confirm 
the results obtained from NGS by real-time PCR analysis. In literature miR-375 
has been reported to be downregulated in head and neck squamous cell carcinoma 




Even though we were not able to confirm some of the results compared 
to miRNA expression studies in different tissue types, our results may be valuable 
for OPSCC research. Due to its unique place among head and neck cancers (HPV 
positivity, lymph node metastasis) expression values of miRNAs can be unique tool 
for characterization of the tumors.  
All methods used for miRNA expression analysis have its advantages and 
disadvantages. Real-time PCR is the most cost effective and more sensitive method 
for miRNA studies but has its limitations in quantity of samples that can be analyzed 
in reaction and especially in low number of target miRNAs. It is clear from our results 
that both high-throughput methods are mostly reliable. The weakness of miRNA 
microarray from our point of view is the inability to quantify miRNAs expressed 
in low quantities and labor-intensive workflow. Small RNA NGS seems to have more 
advantages than miRNA microarray and nowadays it is a preferred method 
of miRNA expression studies for many scientists with its high sensitivity, variability 
and many library preparation kits options on the market. However, small RNA NGS 
requires prior experience with NGS and bioinformatical analysis of the results is very 
complex and time-consuming. From our perspective small RNA NGS is the more 





My doctoral study research activities were focused on investigation of relative 
microRNA expression (and its possible regulation by DNA methylation) in two 
unique sets of samples of head and neck squamous cell carcinoma.  
 
Following up on previously established objectives of the study, I conclude that: 
1. I have successfully used two high-throughput methods (Agilent miRNA 
microarray and small RNA NGS with NEBNext Small RNA Library Prep Kit 
for Illumina) to select significantly deregulated microRNAs 
in oropharyngeal carcinoma samples for further validation. 
A low-throughput method (real-time PCR with TaqManTM Advanced 
Assays) was used to confirm deregulation of previously selected microRNA 
expression in sinonasal squamous cell carcinoma (based on literary review) 
and oropharyngeal squamous cell carcinoma (based on high-throughput 
methods results). 
2. I have examined possibility that miR-145-5p and miR-143-3p deregulation 
is caused by other epigenetic modification – DNA methylation. Methylation 
status of miR-145 gene, miR-143 gene and their host gene (miR-143/145) was 
investigated by methylation specific high-resolution melting analysis. 
I have found no significant relationship between DNA miRNA gene 
methylation status and miRNA expression. Even though, the samples were 
hypermethylated in promotor regions of the genes, the observed 
hypermethylation was not cause of miRNA deregulation. 
3. I have found many correlations between expression of miRNAs 
and recorded clinicopathological data (such as gender, age, occupation, 
HPV status, smoker status, alcohol use, localization and typing of the 
tumor, TNM classification, invasion and recurrence) of the patients using 
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appropriate statistical software. Especially, deregulation of miRNAs 
in advanced stage of the disease were considered relevant (mir-9 and 
miR-150-5p).  Moreover, I have found relationship between significant 
deregulation of several miRNAs (miR-21-5p, miR-9-5p, let-7d-5p, 
miR-137-3p and miR-150-5p) and impaired survival of the patients. 
4. I have concluded that (among others) miR-9 might be the best potential 
biomarker for sinonasal squamous cell carcinoma. The experiment showed 
that both 3’ and 5’ miR-9 strands are abundantly expressed in the tissue, its 
expression was related to survival of the patients and it correlated 
with several clinicopathological parameters. miR-150-5p (among others) 
may be the best potential biomarker for oropharyngeal squamous cell 
carcinoma. miR-150-5p was significantly in both tumor and metastasis 
samples, its low expression in tumor and metastasis samples was associated 
to impaired survival of the patients and it was less expressed in advanced 
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11 Appendices 
11.1  Appendix A: Deregulated miRNAs (Agilent microarray) 
Appendix Table 1. Differentially expressed miRNAs in oropharyngeal 











hsa-miR-3656 16.01 0.0000 hsa-miR-150-5p -17.46 0.0783 
hsa-miR-4530 11.02 0.0000 hsa-miR-142-3p -16.59 0.0608 
hsa-miR-4443 10.37 0.0005 hsa-miR-142-5p -14.79 0.0093 
hsa-miR-6088 10.06 0.0000 hsa-miR-29c-3p -7.40 0.1435 
hsa-miR-4653-3p 9.50 0.0072 hsa-miR-223-3p -6.84 0.0341 
hsa-miR-4430 9.36 0.0012 hsa-miR-3653-3p -5.92 0.0481 
hsa-miR-4281 9.34 0.0000 hsa-miR-29b-3p -5.31 0.1512 
hsa-miR-1207-5p 9.22 0.0001 hsa-let-7g-5p -5.12 0.2814 
hsa-miR-642a-3p 8.90 0.0190 hsa-miR-26b-5p -4.98 0.1827 
hsa-miR-2861 8.80 0.0001 hsa-miR-140-3p -4.91 0.0316 
hsa-miR-6125 8.66 0.0000 hsa-miR-342-3p -4.36 0.2810 
hsa-miR-1915-3p 8.65 0.0000 hsa-miR-29a-3p -4.06 0.4263 
hsa-miR-3665 8.58 0.0000 hsa-miR-101-3p -3.80 0.0625 
hsa-miR-6803-5p 8.58 0.0020 hsa-miR-144-3p -3.70 0.0190 
hsa-miR-6821-5p 8.43 0.0000 hsa-miR-203a-3p -3.62 0.2370 
hsa-miR-1202 8.21 0.0001 hsa-miR-19b-3p -3.60 0.4226 
hsa-miR-4741 8.20 0.0007 hsa-miR-126-3p -3.38 0.3167 
hsa-miR-6087 8.18 0.0001 hsa-miR-30b-5p -3.37 0.2820 
hsa-miR-6090 8.05 0.0000 hsa-miR-15a-5p -3.29 0.2930 
hsa-miR-6800-5p 7.92 0.0001 hsa-miR-146a-5p -3.24 0.3321 
hsa-miR-4687-3p 7.89 0.0001 hsa-miR-19a-3p -3.23 0.2113 
hsa-miR-4763-3p 7.81 0.0000 hsa-miR-145-5p -3.15 0.3393 
hsa-miR-197-5p 7.80 0.0001 hsa-miR-140-5p -2.93 0.0783 
hsa-miR-4497 7.76 0.0000 hsa-miR-195-5p -2.82 0.2745 
hsa-miR-3195 7.69 0.0054 hsa-miR-100-5p -2.80 0.2775 
hsa-miR-1268a 7.52 0.0000 hsa-miR-451a -2.74 0.6041 
hsa-miR-1268b 7.50 0.0001 hsa-miR-365a-3p -2.68 0.1827 
hsa-miR-6749-5p 7.35 0.0003 hsa-miR-4446-3p -2.65 0.2376 
hsa-miR-638 7.28 0.0005 hsa-miR-342-5p -2.61 0.0139 
hsa-miR-6068 7.05 0.0004 hsa-miR-3607-3p -2.61 0.0004 
hsa-miR-1225-5p 7.00 0.0009 hsa-miR-497-5p -2.60 0.2311 
hsa-miR-3960 6.93 0.0001 hsa-let-7i-5p -2.57 0.6065 
hsa-miR-5787 6.80 0.0190 hsa-miR-26a-5p -2.55 0.6609 
 
hsa-miR-762 6.47 0.0005 hsa-miR-664a-5p -2.52 0.1525 
hsa-miR-7107-5p 6.36 0.0040 hsa-miR-30e-5p -2.49 0.4144 
hsa-miR-3162-5p 6.28 0.0001 hsa-miR-107 -2.48 0.4608 
hsa-miR-940 6.21 0.0029 hsa-miR-3607-5p -2.44 0.0040 
hsa-miR-4466 5.99 0.0000 hsa-miR-374a-5p -2.43 0.2197 
hsa-miR-4516 5.89 0.0003 hsa-miR-30c-5p -2.34 0.3272 
hsa-miR-642b-3p 5.83 0.0550 hsa-miR-29c-5p -2.34 0.0004 
hsa-miR-6089 5.83 0.0001 hsa-miR-106b-5p -2.32 0.5338 
hsa-miR-5739 5.83 0.0001 hsa-miR-199a-5p -2.32 0.4487 
hsa-miR-1224-5p 5.69 0.0000 hsa-miR-15b-5p -2.31 0.6191 
hsa-miR-7110-5p 5.61 0.0232 hsa-miR-17-5p -2.25 0.5429 
hsa-miR-1229-5p 5.32 0.0005 hsa-miR-146b-5p -2.24 0.3569 
hsa-miR-6869-5p 5.13 0.0037 hsa-miR-148a-3p -2.23 0.4152 
hsa-miR-4733-5p 5.11 0.0000 hsa-miR-20a-5p -2.23 0.6544 
hsa-miR-205-5p 5.02 0.2879 hsa-miR-186-5p -2.22 0.1171 
hsa-miR-1185-1-3p 4.83 0.0008 hsa-miR-10b-5p -2.21 0.2198 
hsa-miR-4672 4.72 0.0001 hsa-miR-5699-5p -2.17 0.3378 
hsa-miR-4739 4.61 0.0097 hsa-miR-103a-3p -2.14 0.6579 
hsa-miR-7150 4.58 0.0200 hsa-miR-590-5p -2.11 0.0009 
hsa-miR-6775-5p 4.55 0.0008 hsa-miR-361-3p -2.09 0.1166 
hsa-miR-328-5p 4.48 0.0113 hsa-miR-28-5p -2.07 0.0671 
hsa-miR-6085 4.43 0.0003 hsa-miR-425-5p -2.07 0.2863 
hsa-miR-4507 4.37 0.0185 hsa-miR-199a-3p -2.06 0.6569 
hsa-miR-6893-5p 4.26 0.1166 hsa-miR-331-3p -2.03 0.4144 
hsa-miR-6127 4.24 0.0066 hsa-miR-4636 -2.03 0.0118 
hsa-miR-4270 4.19 0.0115 hsa-miR-455-3p -2.02 0.1025 
hsa-miR-937-5p 4.12 0.0000 hsa-let-7f-5p -2.02 0.7588 
hsa-miR-6826-5p 4.04 0.0058 hsa-let-7d-5p -2.02 0.5517 
hsa-miR-1227-5p 4.03 0.0058 
hsa-miR-6891-5p 3.97 0.0031 
hsa-miR-1185-2-3p 3.91 0.0219 
hsa-miR-3940-5p 3.89 0.0001 
hsa-miR-1587 3.85 0.0085 
hsa-miR-6132 3.85 0.0179 
hsa-miR-6124 3.84 0.0136 
hsa-miR-939-5p 3.82 0.0003 
hsa-miR-4505 3.81 0.0069 
hsa-miR-8069 3.81 0.0000 
hsa-miR-4534 3.80 0.0139 
hsa-miR-575 3.79 0.0445 
hsa-miR-4465 3.76 0.1311 
hsa-miR-6786-5p 3.74 0.0096 
hsa-miR-7108-5p 3.74 0.0108 
hsa-miR-7704 3.71 0.0117 
 
hsa-miR-663a 3.64 0.0697 
hsa-miR-6791-5p 3.63 0.0002 
hsa-miR-4788 3.59 0.0050 
hsa-miR-6724-5p 3.57 0.0066 
hsa-miR-6126 3.52 0.0010 
hsa-miR-4632-5p 3.48 0.0017 
hsa-miR-4327 3.43 0.0272 
hsa-miR-4488 3.43 0.0001 
hsa-miR-6812-5p 3.42 0.0020 
hsa-miR-4721 3.41 0.1108 
hsa-miR-3679-5p 3.40 0.0066 
hsa-miR-6510-5p 3.37 0.1166 
hsa-miR-4462 3.37 0.0014 
hsa-miR-4428 3.36 0.0252 
hsa-miR-4459 3.19 0.0993 
hsa-miR-6769b-5p 3.17 0.2071 
hsa-miR-4433a-3p 3.15 0.0192 
hsa-miR-6076 3.13 0.0018 
hsa-miR-6740-5p 3.09 0.1025 
hsa-miR-6165 3.04 0.0005 
hsa-miR-4322 3.03 0.0002 
hsa-miR-188-5p 3.03 0.1968 
hsa-miR-5088-5p 3.02 0.1266 
hsa-miR-7847-3p 3.01 0.0294 
hsa-miR-6794-5p 3.00 0.0588 
hsa-miR-1471 3.00 0.2446 
hsa-miR-1287-5p 2.97 0.0838 
hsa-miR-320c 2.94 0.0341 
hsa-miR-574-3p 2.92 0.4670 
hsa-miR-630 2.89 0.2769 
hsa-miR-6789-5p 2.87 0.0178 
hsa-miR-4463 2.86 0.1577 
hsa-miR-4485-5p 2.85 0.2282 
hsa-miR-125a-3p 2.84 0.1257 
hsa-miR-1275 2.81 0.2311 
hsa-miR-150-3p 2.80 0.0190 
hsa-miR-4417 2.78 0.1357 
hsa-miR-6799-5p 2.78 0.0017 
hsa-miR-6785-5p 2.77 0.2976 
hsa-miR-6727-5p 2.74 0.0536 
hsa-miR-3135b 2.73 0.1630 
hsa-miR-671-5p 2.72 0.2062 
hsa-miR-4695-5p 2.71 0.0275 
hsa-miR-134-5p 2.70 0.0414 
 
hsa-miR-5001-5p 2.70 0.0113 
hsa-miR-8063 2.69 0.1242 
hsa-miR-4442 2.63 0.0349 
hsa-miR-4532 2.61 0.0116 
hsa-miR-6849-5p 2.60 0.0289 
hsa-miR-3188 2.60 0.1074 
hsa-miR-6756-5p 2.53 0.1270 
hsa-miR-4745-5p 2.53 0.1212 
hsa-miR-371b-5p 2.52 0.0166 
hsa-miR-6879-5p 2.52 0.1432 
hsa-miR-5100 2.52 0.2339 
hsa-miR-5006-5p 2.51 0.2733 
hsa-miR-205-3p 2.47 0.0490 
hsa-miR-4634 2.47 0.1910 
hsa-miR-6728-5p 2.46 0.0438 
hsa-miR-371a-5p 2.46 0.0805 
hsa-miR-4271 2.45 0.0249 
hsa-miR-3141 2.43 0.1021 
hsa-miR-1249-5p 2.42 0.2561 
hsa-miR-6752-5p 2.41 0.0671 
hsa-miR-6875-5p 2.41 0.2746 
hsa-miR-3196 2.40 0.0671 
hsa-miR-4787-5p 2.40 0.1751 
hsa-miR-1273g-3p 2.39 0.2863 
hsa-miR-6780b-5p 2.38 0.1758 
hsa-miR-4787-3p 2.36 0.0640 
hsa-miR-4689 2.35 0.3569 
hsa-miR-6850-5p 2.35 0.0805 
hsa-miR-5195-3p 2.32 0.1374 
hsa-miR-4499 2.31 0.1819 
hsa-miR-4746-3p 2.30 0.0671 
hsa-miR-8089 2.29 0.1357 
hsa-miR-1236-5p 2.28 0.1635 
hsa-miR-5196-5p 2.28 0.0603 
hsa-miR-6763-5p 2.27 0.0096 
hsa-miR-4485-3p 2.26 0.3569 
hsa-miR-4800-3p 2.23 0.0000 
hsa-miR-483-5p 2.21 0.3272 
hsa-miR-6831-5p 2.18 0.3088 
hsa-miR-3197 2.17 0.0020 
hsa-miR-7845-5p 2.17 0.0651 
hsa-miR-3648 2.17 0.2500 
hsa-miR-5703 2.16 0.4221 
hsa-miR-1343-5p 2.13 0.1291 
 
hsa-miR-99b-3p 2.11 0.0249 
hsa-miR-4800-5p 2.10 0.1166 
hsa-miR-6075 2.10 0.0281 
hsa-miR-4758-5p 2.10 0.5733 
hsa-miR-208a-5p 2.10 0.1734 
hsa-miR-6867-5p 2.09 0.3272 
hsa-miR-4486 2.09 0.1092 
hsa-miR-8072 2.07 0.4221 
hsa-miR-4257 2.07 0.0805 
hsa-miR-7106-5p 2.06 0.1143 
hsa-miR-1246 2.06 0.4187 
hsa-miR-7159-5p 2.05 0.1074 
hsa-miR-6790-5p 2.05 0.0165 
hsa-miR-4707-5p 2.04 0.0204 
hsa-miR-320a 2.03 0.0640 
hsa-miR-8485 2.00 0.6388 
Bold text marks miRNA selected for future analysis. FC, fold change. 
Appendix Table 2. Differentially expressed miRNAs in oropharyngeal 











hsa-miR-3656 14.51 0.0000 hsa-miR-142-5p -11.31 0.0187 
hsa-miR-4653-3p 11.08 0.0036 hsa-miR-142-3p -9.55 0.1339 
hsa-miR-4430 11.05 0.0006 hsa-miR-133b -8.54 0.0231 
hsa-miR-4530 10.13 0.0001 hsa-miR-150-5p -8.15 0.1989 
hsa-miR-4443 9.37 0.0009 hsa-miR-223-3p -7.20 0.0273 
hsa-miR-6125 9.27 0.0001 hsa-miR-29c-3p -5.76 0.1915 
hsa-miR-6803-5p 9.26 0.0014 hsa-miR-203a-3p -5.72 0.0733 
hsa-miR-3665 8.62 0.0000 hsa-miR-29b-3p -5.22 0.1369 
hsa-miR-2861 8.34 0.0001 hsa-let-7g-5p -4.61 0.2650 
hsa-miR-6088 8.33 0.0001 hsa-miR-342-3p -4.44 0.2223 
hsa-miR-4497 8.15 0.0000 hsa-miR-26b-5p -4.39 0.1989 
hsa-miR-197-5p 7.53 0.0002 hsa-miR-140-3p -4.23 0.0543 
hsa-miR-4281 7.29 0.0002 hsa-miR-1-3p -4.11 0.0484 
hsa-miR-6087 7.28 0.0003 hsa-miR-3653-3p -3.88 0.1382 
hsa-miR-4741 7.22 0.0017 hsa-miR-29a-3p -3.54 0.4198 
hsa-miR-638 7.13 0.0007 hsa-miR-30b-5p -3.35 0.2362 
hsa-miR-1268b 7.01 0.0003 hsa-miR-19b-3p -3.30 0.4019 
hsa-miR-6821-5p 6.86 0.0001 hsa-miR-101-3p -3.29 0.0937 
hsa-miR-6800-5p 6.76 0.0003 hsa-miR-19a-3p -3.05 0.2008 
hsa-miR-642a-3p 6.75 0.0448 hsa-miR-365a-3p -3.00 0.1084 
 
hsa-miR-1915-3p 6.70 0.0002 hsa-miR-126-3p -2.99 0.3205 
hsa-miR-1207-5p 6.66 0.0005 hsa-miR-146a-5p -2.93 0.3280 
hsa-miR-762 6.50 0.0007 hsa-miR-199a-3p -2.80 0.4149 
hsa-miR-1225-5p 6.35 0.0017 hsa-miR-148a-3p -2.79 0.2100 
hsa-miR-6132 6.35 0.0008 hsa-miR-206 -2.72 0.0527 
hsa-miR-6068 6.33 0.0009 hsa-miR-103a-3p -2.65 0.4778 
hsa-miR-3195 6.32 0.0114 hsa-miR-133a-3p -2.63 0.0478 
hsa-miR-6090 6.28 0.0002 hsa-miR-199a-5p -2.61 0.3147 
hsa-miR-3162-5p 6.06 0.0001 hsa-miR-144-3p -2.57 0.1070 
hsa-miR-205-5p 5.98 0.1948 hsa-miR-30c-5p -2.54 0.2197 
hsa-miR-1224-5p 5.92 0.0000 hsa-miR-186-5p -2.54 0.0513 
hsa-miR-7107-5p 5.80 0.0061 hsa-miR-107 -2.53 0.3851 
hsa-miR-574-3p 5.71 0.1432 hsa-miR-3607-5p -2.52 0.0024 
hsa-miR-4687-3p 5.66 0.0009 hsa-let-7i-5p -2.46 0.5543 
hsa-miR-1268a 5.53 0.0001 hsa-miR-140-5p -2.45 0.1378 
hsa-miR-4763-3p 5.49 0.0004 hsa-miR-100-5p -2.41 0.3177 
hsa-miR-6089 5.30 0.0004 hsa-miR-29c-5p -2.41 0.0003 
hsa-miR-1202 5.25 0.0028 hsa-miR-15a-5p -2.39 0.4188 
hsa-miR-5787 5.22 0.0478 hsa-miR-30e-5p -2.36 0.3818 
hsa-miR-940 5.21 0.0070 hsa-miR-374a-5p -2.34 0.2034 
hsa-miR-3960 5.07 0.0010 hsa-miR-331-3p -2.24 0.2685 
hsa-miR-5739 5.06 0.0005 hsa-miR-193b-3p -2.21 0.1935 
hsa-miR-6749-5p 4.88 0.0045 hsa-miR-3607-3p -2.16 0.0047 
hsa-miR-6826-5p 4.72 0.0018 hsa-miR-195-5p -2.14 0.4002 
hsa-miR-4466 4.72 0.0001 hsa-let-7d-5p -2.13 0.4486 
hsa-miR-4507 4.72 0.0113 hsa-miR-199b-5p -2.12 0.2429 
hsa-miR-4465 4.70 0.0602 hsa-miR-4636 -2.11 0.0070 
hsa-miR-4721 4.64 0.0296 hsa-miR-15b-5p -2.11 0.6005 
hsa-miR-1185-1-3p 4.61 0.0013 hsa-miR-10b-5p -2.10 0.2136 
hsa-miR-7110-5p 4.58 0.0484 hsa-miR-145-5p -2.04 0.5416 
hsa-miR-6893-5p 4.54 0.0842 hsa-miR-146b-5p -2.04 0.3697 
hsa-miR-6127 4.48 0.0043 hsa-miR-17-5p -2.03 0.5439 
hsa-miR-6869-5p 4.43 0.0080 hsa-miR-451a -2.01 0.6795 
hsa-miR-642b-3p 4.37 0.1084 
hsa-miR-8485 4.36 0.1802 
hsa-miR-4733-5p 4.35 0.0000 
hsa-miR-6775-5p 4.29 0.0014 
hsa-miR-6769b-5p 4.25 0.0812 
hsa-miR-6126 4.20 0.0003 
hsa-miR-4516 4.19 0.0036 
hsa-miR-4462 4.14 0.0003 
hsa-miR-4428 4.14 0.0066 
hsa-miR-4505 4.14 0.0036 
hsa-miR-4672 4.08 0.0006 
 
hsa-miR-937-5p 3.93 0.0001 
hsa-miR-6812-5p 3.88 0.0007 
hsa-miR-6791-5p 3.85 0.0002 
hsa-miR-4485-5p 3.81 0.0881 
hsa-miR-3135b 3.76 0.0447 
hsa-miR-6085 3.76 0.0013 
hsa-miR-1587 3.69 0.0094 
hsa-miR-1229-5p 3.69 0.0070 
hsa-miR-939-5p 3.65 0.0007 
hsa-miR-6785-5p 3.64 0.1339 
hsa-miR-7150 3.62 0.0553 
hsa-miR-7108-5p 3.61 0.0122 
hsa-miR-3196 3.54 0.0042 
hsa-miR-4327 3.54 0.0206 
hsa-miR-7704 3.50 0.0154 
hsa-miR-1227-5p 3.46 0.0135 
hsa-miR-4485-3p 3.40 0.1031 
hsa-miR-4270 3.40 0.0342 
hsa-miR-6875-5p 3.32 0.0884 
hsa-miR-3940-5p 3.20 0.0007 
hsa-miR-6740-5p 3.18 0.0802 
hsa-miR-6724-5p 3.13 0.0146 
hsa-miR-6076 3.12 0.0019 
hsa-miR-4632-5p 3.08 0.0047 
hsa-miR-8069 3.02 0.0003 
hsa-miR-6124 2.99 0.0506 
hsa-miR-4534 2.98 0.0502 
hsa-miR-5100 2.97 0.1219 
hsa-miR-4788 2.91 0.0199 
hsa-miR-574-5p 2.91 0.1080 
hsa-miR-4299 2.91 0.2100 
hsa-miR-4488 2.90 0.0008 
hsa-miR-8063 2.89 0.0813 
hsa-miR-6780b-5p 2.89 0.0734 
hsa-miR-6891-5p 2.87 0.0278 
hsa-miR-3679-5p 2.85 0.0205 
hsa-miR-1185-2-3p 2.83 0.0912 
hsa-miR-371b-5p 2.78 0.0066 
hsa-miR-6799-5p 2.76 0.0018 
hsa-miR-5006-5p 2.74 0.1838 
hsa-miR-1275 2.72 0.2064 
hsa-miR-1287-5p 2.72 0.1070 
hsa-miR-1273g-3p 2.68 0.1846 
hsa-miR-188-5p 2.67 0.2211 
 
hsa-miR-4746-3p 2.66 0.0222 
hsa-miR-6786-5p 2.62 0.0715 
hsa-miR-6165 2.59 0.0028 
hsa-miR-125a-3p 2.59 0.1476 
hsa-miR-6879-5p 2.56 0.1193 
hsa-miR-141-3p 2.55 0.4992 
hsa-miR-4745-5p 2.54 0.1031 
hsa-miR-1246 2.52 0.2120 
hsa-miR-4739 2.51 0.1432 
hsa-miR-4695-5p 2.51 0.0448 
hsa-miR-5088-5p 2.50 0.1980 
hsa-miR-4459 2.50 0.1913 
hsa-miR-4515 2.50 0.0734 
hsa-miR-5001-5p 2.49 0.0194 
hsa-miR-4800-5p 2.48 0.0387 
hsa-miR-1273f 2.41 0.1310 
hsa-miR-1249-5p 2.39 0.2145 
hsa-miR-8089 2.38 0.1031 
hsa-miR-4322 2.36 0.0045 
hsa-miR-7847-3p 2.31 0.1084 
hsa-miR-7106-5p 2.31 0.0502 
hsa-miR-5585-3p 2.31 0.2044 
hsa-miR-4478 2.31 0.1717 
hsa-miR-1471 2.31 0.3533 
hsa-miR-4442 2.30 0.0755 
hsa-miR-4433a-3p 2.28 0.1080 
hsa-miR-6510-5p 2.28 0.2831 
hsa-miR-6794-5p 2.28 0.1667 
hsa-let-7b-5p 2.26 0.5322 
hsa-miR-371a-5p 2.23 0.1139 
hsa-miR-4271 2.23 0.0478 
hsa-miR-150-3p 2.22 0.0806 
hsa-miR-328-5p 2.22 0.2106 
hsa-miR-6727-5p 2.22 0.1316 
hsa-miR-3141 2.20 0.1339 
hsa-miR-575 2.20 0.2507 
hsa-miR-1281 2.20 0.1994 
hsa-miR-92a-3p 2.17 0.4571 
hsa-miR-4417 2.17 0.2482 
hsa-miR-663a 2.15 0.2999 
hsa-miR-6789-5p 2.14 0.1031 
hsa-miR-6075 2.11 0.0252 
hsa-miR-4758-5p 2.11 0.5082 
hsa-miR-1181 2.09 0.0872 
 
hsa-miR-6763-5p 2.08 0.0199 
hsa-miR-4787-5p 2.05 0.2405 
hsa-miR-4463 2.04 0.3390 
hsa-miR-6756-5p 2.04 0.2322 
hsa-miR-320c 2.01 0.1938 
hsa-miR-6849-5p 2.01 0.1250 
hsa-miR-205-3p 2.00 0.1369 
Bold text marks miRNA selected for future analysis. FC, fold change. 
Appendix Table 3. Differentially expressed miRNAs in oropharyngeal 
metastasis samples compared to tumor samples. 
Name FC Deregulation 
Adjusted P 
Value 
hsa-miR-8485 2.18 0.9954 
hsa-miR-150-5p 2.14 0.9954 
hsa-miR-328-5p -2.02 0.9868 
hsa-miR-133a-3p -2.21 0.8642 
hsa-miR-1-3p -2.53 0.9721 
hsa-miR-206 -3.34 0.2758 
hsa-miR-133b -6.64 0.6251 




11.2 Appendix B: Deregulated miRNAs (small RNA NGS) 
Appendix Table 4. Differentially expressed miRNAs in oropharyngeal 











hsa-miR-196a-5p 22.22 0.0000 hsa-miR-150-5p -9.78 0.0000 
hsa-miR-187-3p 11.26 0.0000 hsa-miR-142-5p -7.45 0.0000 
hsa-miR-615-3p 9.93 0.0000 hsa-miR-342-3p -6.75 0.0000 
hsa-miR-9-5p 8.11 0.0000 hsa-miR-142-3p -6.09 0.0000 
hsa-miR-147b 6.68 0.0000 hsa-miR-1273h-3p -5.55 0.0000 
hsa-miR-377-5p 6.60 0.0009 hsa-miR-150-3p -5.53 0.0000 
hsa-miR-1246 5.80 0.0000 hsa-miR-342-5p -5.51 0.0000 
hsa-miR-205-3p 5.35 0.0002 hsa-miR-138-5p -5.37 0.0000 
hsa-miR-944 4.75 0.0000 hsa-miR-7-1-3p -5.22 0.0000 
hsa-miR-382-5p 4.47 0.0007 hsa-miR-155-5p -5.20 0.0000 
hsa-miR-7641 4.25 0.0000 hsa-miR-766-3p -5.08 0.0000 
hsa-miR-409-3p 4.06 0.0004 hsa-miR-140-3p -4.69 0.0000 
hsa-miR-206 3.92 0.0446 hsa-miR-26b-5p -4.35 0.0000 
hsa-miR-141-5p 3.80 0.0001 hsa-miR-223-5p -4.12 0.0000 
hsa-miR-4488 3.79 0.0027 hsa-miR-29b-3p -4.09 0.0000 
hsa-miR-1307-5p 3.79 0.0006 hsa-miR-140-5p -4.08 0.0000 
hsa-miR-6087 3.75 0.0007 hsa-miR-26a-5p -3.93 0.0000 
hsa-miR-493-3p 3.70 0.0011 hsa-miR-26b-3p -3.84 0.0000 
hsa-miR-141-3p 3.56 0.0001 hsa-miR-3613-3p -3.74 0.0001 
hsa-miR-485-5p 3.42 0.0117 hsa-miR-184 -3.74 0.0090 
hsa-miR-4492 3.37 0.0009 hsa-miR-532-3p -3.64 0.0000 
hsa-miR-134-5p 3.30 0.0046 hsa-miR-29a-3p -3.63 0.0000 
oan-miR-1386 3.22 0.0000 hsa-miR-664b-3p -3.63 0.0001 
hsa-miR-4497 3.18 0.0000 hsa-miR-361-3p -3.57 0.0000 
hsa-miR-370-3p 3.18 0.0089 hsa-miR-671-3p -3.51 0.0036 
hsa-miR-196b-5p 3.11 0.0002 hsa-let-7g-5p -3.48 0.0000 
hsa-miR-127-3p 3.06 0.0052 hsa-miR-504-5p -3.47 0.0001 
hsa-miR-4508 3.05 0.0031 hsa-miR-194-5p -3.43 0.0001 
hsa-miR-375 2.99 0.0218 hsa-miR-191-5p -3.41 0.0000 
hsa-miR-27b-5p 2.84 0.0001 hsa-miR-28-5p -3.40 0.0000 
hsa-miR-127-5p 2.80 0.0183 hsa-miR-145-5p -3.39 0.0000 
hsa-miR-381-3p 2.79 0.0257 hsa-miR-181a-5p -3.39 0.0000 
hsa-miR-224-5p 2.73 0.0008 hsa-miR-590-3p -3.36 0.0005 
hsa-miR-1-3p 2.72 0.1154 hsa-miR-195-5p -3.35 0.0001 
hsa-miR-210-3p 2.71 0.0000 hsa-miR-664a-3p -3.34 0.0010 
hsa-miR-503-5p 2.63 0.0022 hsa-miR-15a-5p -3.27 0.0000 
hsa-miR-3687 2.62 0.0029 hsa-miR-192-5p -3.26 0.0000 
hsa-miR-34c-5p 2.57 0.0002 hsa-miR-576-5p -3.26 0.0001 
hsa-miR-1180-3p 2.55 0.0003 hsa-miR-1271-5p -3.20 0.0027 
hsa-miR-33a-5p 2.50 0.0005 hsa-miR-223-3p -3.19 0.0000 
hsa-miR-379-5p 2.48 0.0229 hsa-miR-30c-5p -3.14 0.0000 
hsa-miR-200a-3p 2.46 0.0010 hsa-miR-361-5p -3.09 0.0000 
hsa-miR-1972 2.45 0.0160 hsa-miR-374a-5p -3.08 0.0001 
 
hsa-miR-133a-3p 2.45 0.1910 hsa-miR-181a-3p -3.04 0.0000 
hsa-miR-1273g-3p 2.40 0.0003 hsa-miR-139-5p -3.03 0.0004 
hsa-miR-432-5p 2.39 0.0938 hsa-miR-20a-5p -2.97 0.0000 
hsa-miR-27a-5p 2.36 0.0006 hsa-miR-144-5p -2.95 0.0192 
hsa-miR-133a-5p 2.33 0.2242 hsa-miR-574-3p -2.94 0.0000 
hsa-miR-3960 2.29 0.0638 hsa-miR-197-3p -2.93 0.0000 
hsa-miR-200a-5p 2.23 0.0072 hsa-miR-455-3p -2.92 0.0000 
hsa-miR-378a-3p 2.22 0.0164 hsa-miR-451a -2.90 0.0073 
hsa-miR-185-3p 2.19 0.0277 hsa-miR-331-3p -2.85 0.0000 
hsa-miR-450b-5p 2.18 0.0091 hsa-miR-582-5p -2.84 0.0014 
hsa-miR-299-3p 2.17 0.1285 hsa-miR-1260b -2.84 0.0000 
hsa-miR-452-5p 2.15 0.0003 hsa-miR-32-5p -2.82 0.0005 
hsa-miR-1291 2.11 0.0021 hsa-miR-30e-3p -2.74 0.0000 
hsa-miR-424-3p 2.11 0.0938 hsa-miR-16-5p -2.69 0.0000 
hsa-miR-21-3p 2.09 0.0043 hsa-miR-100-5p -2.68 0.0000 
hsa-miR-675-5p 2.08 0.1311 hsa-miR-135a-5p -2.67 0.0092 
hsa-miR-3656 2.07 0.0553 hsa-miR-339-3p -2.65 0.0000 
hsa-miR-452-3p 2.01 0.0447 hsa-miR-514a-3p -2.65 0.0632 
     hsa-miR-338-5p -2.62 0.0065 
     hsa-miR-101-3p -2.62 0.0001 
     hsa-miR-484 -2.61 0.0021 
     hsa-miR-128-3p -2.54 0.0008 
     hsa-miR-126-5p -2.53 0.0010 
     hsa-miR-330-3p -2.51 0.0007 
     hsa-miR-625-3p -2.50 0.0004 
     hsa-miR-598-3p -2.48 0.0006 
     hsa-miR-181b-5p -2.40 0.0000 
     hsa-miR-505-3p -2.38 0.0000 
     hsa-let-7e-5p -2.38 0.0015 
     hsa-miR-744-5p -2.38 0.0005 
     hsa-miR-186-5p -2.37 0.0000 
     hsa-miR-618 -2.37 0.0417 
     hsa-miR-92a-3p -2.36 0.0001 
     hsa-miR-148b-3p -2.35 0.0135 
     hsa-miR-146a-5p -2.34 0.0001 
     hsa-miR-548e-3p -2.34 0.0032 
     hsa-miR-125a-5p -2.31 0.0003 
     hsa-miR-454-3p -2.30 0.0005 
     hsa-miR-29c-3p -2.30 0.0000 
     hsa-miR-6842-3p -2.29 0.0013 
     hsa-miR-589-5p -2.28 0.0004 
     hsa-let-7g-3p -2.27 0.0071 
     hsa-miR-628-5p -2.26 0.0204 
     hsa-miR-125b-5p -2.25 0.0003 
     hsa-miR-30b-5p -2.23 0.0001 
     hsa-miR-497-5p -2.22 0.0014 
     hsa-miR-660-5p -2.19 0.0001 
     hsa-miR-126-3p -2.17 0.0000 
     hsa-miR-548o-3p -2.17 0.0167 
     hsa-miR-146b-5p -2.17 0.0013 
     hsa-miR-340-3p -2.13 0.0908 
     hsa-miR-339-5p -2.13 0.0000 
 
     hsa-miR-374a-3p -2.12 0.0094 
     hsa-miR-19b-3p -2.09 0.0023 
     hsa-miR-548f-5p -2.09 0.0356 
     hsa-miR-218-5p -2.06 0.0001 
     hsa-let-7a-3p -2.06 0.0340 
     hsa-miR-28-3p -2.05 0.0000 
     hsa-miR-144-3p -2.05 0.0882 
     hsa-let-7a-5p -2.03 0.0041 
     hsa-miR-32-3p -2.03 0.0402 
     hsa-miR-221-5p -2.02 0.0013 
     hsa-miR-1249-3p -2.02 0.0163 
     hsa-miR-3615 -2.01 0.0164 
Bold text marks miRNA selected for future analysis. FC, fold change. 
Appendix Table 5. Differentially expressed miRNAs in oropharyngeal 











hsa-miR-615-3p 19.93 0.0000 hsa-miR-206 -25.13 0.0000 
hsa-miR-196a-5p 19.34 0.0000 hsa-miR-133a-5p -14.09 0.0000 
hsa-miR-1269a 12.84 0.0018 hsa-miR-150-5p -9.18 0.0000 
hsa-miR-147b 12.50 0.0000 hsa-miR-184 -8.26 0.0000 
hsa-miR-9-5p 11.23 0.0000 hsa-miR-766-3p -5.90 0.0000 
hsa-miR-7641 7.04 0.0000 hsa-miR-142-5p -5.64 0.0000 
hsa-miR-944 6.62 0.0000 hsa-miR-342-3p -5.49 0.0000 
hsa-miR-1246 6.56 0.0000 hsa-miR-135a-5p -4.70 0.0002 
hsa-miR-141-5p 6.07 0.0000 hsa-miR-140-3p -4.63 0.0000 
hsa-miR-493-3p 5.77 0.0004 hsa-miR-155-5p -4.43 0.0000 
hsa-miR-214-5p 5.47 0.0000 hsa-miR-150-3p -4.36 0.0000 
hsa-miR-205-3p 5.24 0.0000 hsa-miR-26b-5p -4.16 0.0000 
hsa-miR-141-3p 4.77 0.0000 hsa-miR-4521 -4.06 0.0000 
hsa-miR-187-3p 4.71 0.0018 hsa-miR-139-5p -3.87 0.0000 
hsa-miR-196b-5p 4.62 0.0000 hsa-miR-7-1-3p -3.75 0.0000 
hsa-miR-4508 4.35 0.0002 hsa-miR-26a-5p -3.69 0.0000 
hsa-miR-370-3p 4.34 0.0019 hsa-miR-664b-3p -3.67 0.0000 
hsa-miR-6087 4.30 0.0002 hsa-miR-664a-3p -3.64 0.0000 
hsa-miR-3196 4.10 0.0018 hsa-miR-128-3p -3.42 0.0000 
hsa-miR-27b-5p 4.06 0.0000 hsa-miR-361-3p -3.37 0.0000 
hsa-miR-493-5p 3.68 0.0041 hsa-miR-375 -3.36 0.0086 
hsa-miR-27a-5p 3.63 0.0000 hsa-miR-30c-5p -3.36 0.0000 
hsa-miR-1972 3.39 0.0007 hsa-miR-576-5p -3.34 0.0001 
hsa-miR-127-5p 3.24 0.0085 hsa-miR-484 -3.34 0.0000 
hsa-miR-382-5p 3.24 0.0074 hsa-miR-144-5p -3.32 0.0033 
hsa-miR-210-3p 3.23 0.0000 hsa-miR-28-5p -3.29 0.0000 
hsa-miR-3687 3.21 0.0012 hsa-miR-625-3p -3.26 0.0000 
hsa-miR-409-3p 3.16 0.0043 hsa-miR-191-5p -3.25 0.0000 
hsa-miR-224-5p 3.14 0.0015 hsa-miR-1271-5p -3.25 0.0000 
 
hsa-miR-134-5p 3.12 0.0058 hsa-miR-342-5p -3.20 0.0000 
hsa-miR-33a-5p 3.01 0.0000 hsa-miR-142-3p -3.16 0.0000 
hsa-miR-96-5p 2.96 0.0002 hsa-miR-26b-3p -3.16 0.0000 
hsa-miR-21-3p 2.96 0.0000 hsa-let-7g-5p -3.10 0.0000 
hsa-miR-6510-3p 2.92 0.0112 hsa-miR-29a-3p -3.09 0.0000 
hsa-miR-1307-5p 2.91 0.0010 hsa-miR-1-3p -3.06 0.0700 
hsa-miR-452-5p 2.86 0.0000 hsa-miR-3615 -3.01 0.0000 
hsa-miR-1291 2.85 0.0000 hsa-miR-504-5p -3.01 0.0001 
hsa-miR-452-3p 2.84 0.0029 hsa-miR-532-3p -2.99 0.0001 
oan-miR-1386 2.81 0.0000 hsa-miR-145-5p -2.96 0.0000 
hsa-miR-200a-5p 2.80 0.0043 hsa-miR-330-3p -2.90 0.0000 
hsa-miR-200a-3p 2.79 0.0009 hsa-miR-181a-5p -2.90 0.0000 
hsa-miR-4492 2.78 0.0031 hsa-miR-20a-5p -2.89 0.0000 
hsa-miR-378g 2.75 0.0294 hsa-miR-194-5p -2.88 0.0000 
hsa-miR-4497 2.74 0.0002 hsa-miR-223-3p -2.85 0.0000 
hsa-miR-127-3p 2.73 0.0185 hsa-miR-133a-3p -2.82 0.1767 
hsa-miR-432-5p 2.72 0.0461 hsa-miR-140-5p -2.82 0.0000 
hsa-miR-224-3p 2.71 0.0011 hsa-miR-29b-3p -2.80 0.0000 
hsa-miR-23b-5p 2.60 0.0149 hsa-miR-339-3p -2.78 0.0000 
hsa-miR-4488 2.55 0.0204 hsa-miR-486-5p -2.78 0.0070 
hsa-miR-582-3p 2.48 0.0050 hsa-miR-181a-3p -2.73 0.0000 
hsa-miR-3182 2.43 0.0115 hsa-miR-223-5p -2.70 0.0000 
hsa-miR-135b-3p 2.41 0.0228 hsa-miR-361-5p -2.69 0.0001 
hsa-miR-1180-3p 2.40 0.0031 hsa-miR-30e-3p -2.68 0.0000 
hsa-miR-9-3p 2.38 0.0107 hsa-miR-671-3p -2.61 0.0115 
hsa-miR-4443 2.35 0.0125 hsa-miR-138-5p -2.60 0.0009 
hsa-miR-5585-3p 2.33 0.0035 hsa-miR-92a-3p -2.55 0.0000 
hsa-miR-200b-5p 2.31 0.0058 hsa-miR-340-3p -2.54 0.0143 
hsa-miR-182-5p 2.30 0.0056 hsa-miR-29b-2-5p -2.50 0.0005 
hsa-miR-10a-3p 2.28 0.0169 hsa-miR-451a -2.43 0.0148 
hsa-miR-576-3p 2.27 0.0132 hsa-miR-15b-5p -2.41 0.0277 
hsa-miR-514a-3p 2.27 0.1099 hsa-miR-125b-5p -2.40 0.0000 
hsa-miR-34c-5p 2.27 0.0010 hsa-miR-148b-3p -2.40 0.0026 
hsa-miR-200c-3p 2.24 0.0158 hsa-miR-195-5p -2.39 0.0011 
hsa-miR-450b-5p 2.17 0.0119 hsa-miR-125a-5p -2.36 0.0000 
hsa-miR-1273g-3p 2.16 0.0010 hsa-miR-1249-3p -2.27 0.0059 
hsa-miR-183-5p 2.14 0.0209 hsa-miR-197-3p -2.25 0.0002 
efu-miR-9226 2.13 0.0170 hsa-miR-455-3p -2.22 0.0025 
hsa-miR-758-3p 2.12 0.1265 hsa-miR-107 -2.16 0.0240 
hsa-miR-25-5p 2.12 0.0224 hsa-miR-590-3p -2.10 0.0250 
hsa-miR-3960 2.11 0.1265 hsa-miR-331-3p -2.08 0.0108 
hsa-miR-10a-5p 2.06 0.0036 hsa-miR-129-5p -2.06 0.0416 
hsa-miR-200b-3p 2.06 0.0101 hsa-miR-328-3p -2.04 0.0019 
hsa-miR-151a-3p 2.05 0.0097 hsa-miR-425-5p -2.02 0.0012 
hsa-miR-24-1-5p 2.03 0.1231 hsa-miR-192-5p -2.02 0.0008 
hsa-miR-149-5p 2.00 0.0159 hsa-let-7d-5p -2.01 0.0000 
   hsa-miR-181b-5p -2.01 0.0001 
   hsa-let-7a-5p -2.00 0.0011 
Bold text marks miRNA selected for future analysis. FC, fold change. 
 
Appendix Table 6. Differentially expressed miRNAs in oropharyngeal 
metastasis samples compared to tumor samples.  
Name FC Deregulation 
Adjusted P 
Value 
hsa-miR-514a-3p 2.89 0.0350 
hsa-miR-214-5p 2.42 0.1528 
hsa-miR-218-5p 2.42 0.0245 
hsa-miR-96-5p 2.18 0.1151 
hsa-miR-208b-3p -2.01 0.4584 
hsa-miR-95-3p -2.02 0.4584 
hsa-miR-377-5p -2.12 0.5103 
hsa-miR-4521 -2.15 0.2121 
hsa-miR-381-3p -2.26 0.3189 
hsa-miR-675-5p -2.46 0.2296 
hsa-miR-133a-5p -2.86 0.0779 
hsa-miR-129-5p -2.97 0.0616 
hsa-miR-133a-3p -3.17 0.0350 
hsa-miR-206 -3.39 0.0194 
bta-miR-2889 -3.67 0.0039 
hsa-miR-4532 -3.88 0.0015 
hsa-miR-486-5p -4.16 0.0018 
hsa-miR-1-3p -4.46 0.0018 
hsa-miR-375 -8.12 0.0000 
Bold text marks miRNA selected for future analysis. FC, fold change. 
 
